

**Supplementary Note S1: Reference list of literatures supporting  
proposed cluster infection-disease association with respect to  
individual component virus**

**V1 Respiratory Syncytial Virus and Chronic kidney disease**

1.Segalés, J. *et al.* Porcine dermatitis and nephropathy syndrome in Spain. *Vet. Rec.* **142**, 483–486 (1998).

**V1 Respiratory Syncytial Virus and Coronary heart disease**

1.Bogomolov, B. P., Mol'kova, T. N. & Deviatkin, A. V. [On changes in the cardiovascular system of patients with respiratory syncytial infection]. *Klin Med (Mosk)* **79**, 28–30 (2001).

**V1 Respiratory Syncytial Virus and Inflammatory bowel disease**

1.De La Motte, C. A., Hascall, V. C., Calabro, A., Yen-Lieberman, B. & Strong, S. A. Mononuclear leukocytes preferentially bind via CD44 to hyaluronan on human intestinal mucosal smooth muscle cells after virus infection or treatment with poly(I:C). *J. Biol. Chem.* **274**, 30747–30755 (1999).

**V1 Respiratory Syncytial Virus and Multiple sclerosis**

1.Schauf, V., Schauf, C. L., Mizen, M. & Davis, F. A. Decreased cell-mediated immunity to respiratory syncytial virus in multiple sclerosis. *Acta Neurol. Scand.* **64**, 383–393 (1981).

2.Kaufman, M. D. Do microbes with peptides mimicking myelin cause multiple sclerosis if the T cell response to their unique peptides is limited? *J. Theor. Biol.* **193**, 691–708 (1998).

3.Dhib-Jalbut, S. & Jacobson, S. Cytotoxic T cells in paramyxovirus infection of humans. *Curr. Top. Microbiol. Immunol.* **189**, 109–121 (1994).

4.Bernard, C. C., Townsend, E., Randell, V. B. & Williamson, H. G. Do antibodies to myelin basic protein isolated from multiple sclerosis cross-react with measles and other common virus antigens? *Clin. Exp. Immunol.* **52**, 98–106 (1983).

5.Arnadottir, T. *et al.* Measles and rubella virus antibodies in patients with multiple sclerosis. A longitudinal study of serum and CSF specimens by radioimmunoassay. *Arch. Neurol.* **36**, 261–265 (1979).

**V1 Respiratory Syncytial Virus and Systemic lupus erythematosus**

1. Tamura, N., Sekigawa, I., Hashimoto, H., Yamamoto, N. & Kira, S. Syncytial cell formation in vivo by type C retroviral particles in the systemic lupus erythematosus (SLE) lung. *Clin. Exp. Immunol.* **107**, 474–479 (1997).

2. Cremer, N. E., Hurwitz, D., Quismorio, F. P., Lennette, E. H. & Friou, G. J. Antiviral antibodies in rheumatoid synovial fluid and cryoprecipitates. *Clin. Exp. Immunol.* **18**, 27–37 (1974).

3. Corrales Torres, A. J., el Amrani, A., Herranz Marín, M. T. & Jiménez-Alonso, J. [Respiratory syncytial virus infection in a patient with systemic lupus erythematosus]. *An Med Interna* **11**, 206 (1994).

## **V1 Respiratory Syncytial Virus and Type 2 diabetes**

1. Bouwman, J. J. M., Visseren, F. L. J., Bouter, K. P. & Diepersloot, R. J. A. Infection-induced inflammatory response of adipocytes in vitro. *Int J Obes (Lond)* **32**, 892–901 (2008).

## **V1 Vesicular Stomatitis Virus and Chronic kidney disease**

1. Zaczęńska, E. *et al.* Innate antiviral immunity is not impaired in patients with chronic renal failure on hemodialysis. *Nephron Clin Pract* **101**, c207–210 (2005).

2. Pomeranz, A. *et al.* Antiviral activity of mice with chronic renal failure--an assessment using peritoneal effluents. *Clin. Nephrol.* **41**, 237–240 (1994).

## **V1 Vesicular Stomatitis Virus and Coronary heart disease**

1. Scherer, C. F. C. *et al.* Vesicular stomatitis New Jersey virus (VSNJV) infects keratinocytes and is restricted to lesion sites and local lymph nodes in the bovine, a natural host. *Vet. Res.* **38**, 375–390 (2007).

2. Reis, J. L., Jr, Rodriguez, L. L., Mead, D. G., Smoliga, G. & Brown, C. C. Lesion development and replication kinetics during early infection in cattle inoculated with Vesicular stomatitis New Jersey virus via scarification and black fly (*Simulium vittatum*) bite. *Vet. Pathol.* **48**, 547–557 (2011).

3. Moshonov, S. *et al.* Immunological challenge with virus initiates leukotriene C4 production in the heart and induces cardiomyolysis in guinea pigs. *Prostaglandins Leukot Med* **25**, 17–26 (1986).

4. Mead, D. G. *et al.* Experimental transmission of vesicular stomatitis New Jersey virus from *Simulium vittatum* to cattle: clinical outcome is influenced by site of insect feeding. *J. Med. Entomol.* **46**, 866–872 (2009).

## **V1 Vesicular Stomatitis Virus and Multiple sclerosis**

1. Vervliet, G., Carton, H., Meulepas, E. & Billiau, A. Interferon production by cultured peripheral leucocytes of MS patients. *Clin. Exp. Immunol.* **58**, 116–126

(1984).

2. Dal Canto, M. C. & Rabinowitz, S. G. Experimental models of virus-induced demyelination of the central nervous system. *Ann. Neurol.* **11**, 109–127 (1982).

## **V1 Vesicular Stomatitis Virus and Systemic lupus erythematosus**

1. Wilusz, J., Kurilla, M. G. & Keene, J. D. A host protein (La) binds to a unique species of minus-sense leader RNA during replication of vesicular stomatitis virus. *Proc. Natl. Acad. Sci. U.S.A.* **80**, 5827–5831 (1983).

2. Kurilla, M. G. & Keene, J. D. The leader RNA of vesicular stomatitis virus is bound by a cellular protein reactive with anti-La lupus antibodies. *Cell* **34**, 837–845 (1983).

3. Huang, S. C. *et al.* Immunization with vesicular stomatitis virus nucleocapsid protein induces autoantibodies to the 60 kD Ro ribonucleoprotein particle. *J. Investig. Med.* **43**, 151–158 (1995).

4. Hardgrave, K. L., Neas, B. R., Scofield, R. H. & Harley, J. B. Antibodies to vesicular stomatitis virus proteins in patients with systemic lupus erythematosus and in normal subjects. *Arthritis Rheum.* **36**, 962–970 (1993).

## **V2 Enterovirus 71 and Attention deficit hyperactivity disorder**

1. Gau, S. S.-F. *et al.* Attention-deficit/hyperactivity-related symptoms among children with enterovirus 71 infection of the central nervous system. *Pediatrics* **122**, e452–458 (2008).

## **V2 Enterovirus 71 and Multiple sclerosis**

1. Verhey, L. H. & Banwell, B. L. Inflammatory, vascular, and infectious myelopathies in children. *Handb Clin Neurol* **112**, 999–1017 (2013).

2. Norrby, E. *et al.* Comparison of antibodies against different viruses in cerebrospinal fluid and serum samples from patients with multiple sclerosis. *Infect. Immun.* **10**, 688–694 (1974).

3. Greenlee, J. E. Encephalitis and postinfectious encephalitis. *Continuum (Minneapolis)* **18**, 1271–1289 (2012).

## **V2 Hepatitis A Virus and Multiple sclerosis**

1. Schattner, A. Consequence or coincidence? The occurrence, viruses and significance of autoimmune manifestations after viral vaccines. *Vaccine* **23**, 3876–3886 (2005).

2. Meyers, J. H., Sabatos, C. A., Chakravarti, S. & Kuchroo, V. K. The TIM gene family regulates autoimmune and allergic diseases. *Trends Mol Med* **11**, 362–369 (2005).

3.Bach, J.-F. Infections and autoimmune diseases. *J. Autoimmun.* **25 Suppl**, 74–80 (2005).

## **V2 Herpesvirus 8, Human and Crohn's disease**

1.Svrcek, M., Tired, E., Bennis, M., Guyot, P. & Fléjou, J.-F. KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case. *Dis. Colon Rectum* **52**, 154–158 (2009).

2.Rodríguez-Peláez, M. *et al.* Kaposi's sarcoma: an opportunistic infection by human herpesvirus-8 in ulcerative colitis. *J Crohns Colitis* **4**, 586–590 (2010).

3.Pioche, M. *et al.* Human herpesvirus 8-associated colorectal Kaposi's sarcoma occurring in a drug-induced immunocompromised patient with refractory ulcerative colitis: report of a new case and review of the literature. *Inflamm. Bowel Dis.* **19**, E12–15 (2013).

4.Mergan, F. *et al.* Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis. *J. Pediatr. Surg.* **40**, 1581–1586 (2005).

5.Lavagna, A. *et al.* The hazardous burden of Herpesviridae in inflammatory bowel disease: the case of refractory severe ulcerative colitis. *Dig Liver Dis* **38**, 887–893 (2006).

6.Bursics, A. *et al.* HHV-8 positive, HIV negative disseminated Kaposi's sarcoma complicating steroid dependent ulcerative colitis: a successfully treated case. *Gut* **54**, 1049–1050 (2005).

## **V2 Herpesvirus 8, Human and Inflammatory bowel disease**

1.Svrcek, M., Tired, E., Bennis, M., Guyot, P. & Fléjou, J.-F. KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case. *Dis. Colon Rectum* **52**, 154–158 (2009).

2.Rodríguez-Peláez, M. *et al.* Kaposi's sarcoma: an opportunistic infection by human herpesvirus-8 in ulcerative colitis. *J Crohns Colitis* **4**, 586–590 (2010).

3.Pioche, M. *et al.* Human herpesvirus 8-associated colorectal Kaposi's sarcoma occurring in a drug-induced immunocompromised patient with refractory ulcerative colitis: report of a new case and review of the literature. *Inflamm. Bowel Dis.* **19**, E12–15 (2013).

4.Mergan, F. *et al.* Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis. *J. Pediatr. Surg.* **40**, 1581–1586 (2005).

5.Lavagna, A. *et al.* The hazardous burden of Herpesviridae in inflammatory bowel disease: the case of refractory severe ulcerative colitis. *Dig Liver Dis* **38**, 887–893 (2006).

6.Bursics, A. *et al.* HHV-8 positive, HIV negative disseminated Kaposi's sarcoma complicating steroid dependent ulcerative colitis: a successfully treated case. *Gut* **54**, 1049–1050 (2005).

## **V2 Herpesvirus 8, Human and Multiple sclerosis**

- 1.Sola, P. *et al.* New insights into the viral theory of amyotrophic lateral sclerosis: study on the possible role of Kaposi's sarcoma-associated virus/human herpesvirus 8. *Eur. Neurol.* **47**, 108–112 (2002).
- 2.Pietropaolo, V. *et al.* Detection of human herpesviruses and polyomaviruses DNA in a group of patients with relapsing-remitting multiple sclerosis. *New Microbiol.* **28**, 199–203 (2005).
- 3.Opsahl, M. L. & Kennedy, P. G. E. Investigating the presence of human herpesvirus 7 and 8 in multiple sclerosis and normal control brain tissue. *J. Neurol. Sci.* **240**, 37–44 (2006).
- 4.Olut, A. I., Ozünlü, H., Tan, E. & Kocagöz, T. [Human herpesvirus-8 DNA in patients with certain demyelinating disorders]. *Mikrobiyol Bul* **39**, 169–174 (2005).
- 5.Merelli, E. *et al.* Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults and children. *J. Neurol.* **244**, 450–454 (1997).
- 6.Enbom, M. Multiple sclerosis and Kaposi's sarcoma--chronic diseases associated with new human herpesviruses? *Scand. J. Infect. Dis.* **33**, 648–658 (2001).
- 7.Bergström, T. [Recently discovered herpes viruses explain the etiology of well-known diseases]. *Tidsskr. Nor. Laegeforen.* **119**, 4463–4466 (1999).
- 8.Bergström, T. [HHV 6,7 and 8. Recently discovered herpesviruses explain the etiology of well-known diseases]. *Lakartidningen* **96**, 3161–3165 (1999).
- 9.Ben Fredj, N. *et al.* Identification of human herpesviruses 1 to 8 in Tunisian multiple sclerosis patients and healthy blood donors. *J. Neurovirol.* **18**, 12–19 (2012).
- 10.Alvarez, R. *et al.* [Detection of viral genomes of the Herpesviridae family in multiple sclerosis patients by means of the polymerase chain reaction (PCR)]. *Enferm. Infecc. Microbiol. Clin.* **18**, 223–228 (2000).

## **V2 Herpesvirus 8, Human and Type 2 diabetes**

- 1.Sobngwi, E. *et al.* Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-saharan africans. *JAMA* **299**, 2770–2776 (2008).

## **V2 Measles Virus and Attention deficit hyperactivity disorder**

- 1.Yazbak, F. E. & Yazbak, K. Live virus vaccination near a pregnancy: flawed policies, tragic results. *Med. Hypotheses* **59**, 283–288 (2002).
- 2.Arpino, C., Marzio, M., D'Argenzio, L., Longo, B. & Curatolo, P. Exanthematic diseases during pregnancy and attention-deficit/hyperactivity disorder (ADHD). *Eur. J. Paediatr. Neurol.* **9**, 363–365 (2005).

## **V2 Measles Virus and Crohn's disease**

1. Wakefield, A. J., Montgomery, S. M. & Pounder, R. E. Crohn's disease: the case for measles virus. *Ital J Gastroenterol Hepatol* **31**, 247–254 (1999).
2. Wagner, J., Sim, W. H., Lee, K. J. & Kirkwood, C. D. Current knowledge and systematic review of viruses associated with Crohn's disease. *Rev. Med. Virol.* **23**, 145–171 (2013).
3. Van Kruiningen, H. J. *et al.* Virus serology in familial Crohn disease. *Scand. J. Gastroenterol.* **35**, 403–407 (2000).
4. Selby, W. Pathogenesis and therapeutic aspects of Crohn's disease. *Vet. Microbiol.* **77**, 505–511 (2000).
5. Robertson, D. J. & Sandler, R. S. Measles virus and Crohn's disease: a critical appraisal of the current literature. *Inflamm. Bowel Dis.* **7**, 51–57 (2001).
6. Nielsen, S. E., Nielsen, O. H., Vainer, B. & Claesson, M. H. [Inflammatory bowel disease--do microorganisms play a role?]. *Ugeskr. Laeg.* **164**, 5947–5950 (2002).
7. Lavy, A. *et al.* Measles is more prevalent in Crohn's disease patients. A multicentre Israeli study. *Dig Liver Dis* **33**, 472–476 (2001).
8. Iizuka, M. *et al.* Immunohistochemical analysis of the distribution of measles related antigen in the intestinal mucosa in inflammatory bowel disease. *Gut* **46**, 163–169 (2000).
9. Ghosh, S., Armitage, E., Wilson, D., Minor, P. D. & Afzal, M. A. Detection of persistent measles virus infection in Crohn's disease: current status of experimental work. *Gut* **48**, 748–752 (2001).
10. Folwaczny, C. *et al.* Endothelial cell autoantibodies are a marker of disease susceptibility in inflammatory bowel disease but apparently not linked to persistent measles virus infection. *Clin. Immunol.* **95**, 197–202 (2000).
11. Fisher, N. C., Yee, L., Nightingale, P., McEwan, R. & Gibson, J. A. Measles virus serology in Crohn's disease. *Gut* **41**, 66–69 (1997).
12. Daszak, P. *et al.* Detection and comparative analysis of persistent measles virus infection in Crohn's disease by immunogold electron microscopy. *J. Clin. Pathol.* **50**, 299–304 (1997).
13. Bernstein, C. N., Rawsthorne, P. & Blanchard, J. F. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. *Inflamm. Bowel Dis.* **13**, 759–762 (2007).
14. Afzal, M. A., Minor, P. D., Armitage, E. & Ghosh, S. Measles virus and Crohn's disease. *Gut* **44**, 896–897 (1999).
15. Afzal, M. A., Armitage, E., Ghosh, S., Williams, L. C. & Minor, P. D. Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease. *J. Med. Virol.* **62**, 377–382 (2000).

## **V2 Measles Virus and Inflammatory bowel disease**

1. Wakefield, A. J. & Montgomery, S. M. Measles virus as a risk for inflammatory bowel disease: an unusually tolerant approach. *Am. J. Gastroenterol.* **95**, 1389–1392 (2000).

- 2.Uhlmann, V. *et al.* Potential viral virusic mechanism for new variant inflammatory bowel disease. *MP, Mol. Pathol.* **55**, 84–90 (2002).
- 3.Schattner, A. Consequence or coincidence? The occurrence, viruses and significance of autoimmune manifestations after viral vaccines. *Vaccine* **23**, 3876–3886 (2005).
- 4.Pardi, D. S. *et al.* Early measles virus infection is associated with the development of inflammatory bowel disease. *Am. J. Gastroenterol.* **95**, 1480–1485 (2000).
- 5.Nielsen, S. E., Nielsen, O. H., Vainer, B. & Claesson, M. H. [Inflammatory bowel disease--do microorganisms play a role?]. *Ugeskr. Laeg.* **164**, 5947–5950 (2002).
- 6.Montgomery, S. M., Morris, D. L., Pounder, R. E. & Wakefield, A. J. Paramyxovirus infections in childhood and subsequent inflammatory bowel disease. *Gastroenterology* **116**, 796–803 (1999).
- 7.Lione, A. & Scialli, A. R. Perinatal exposure to measles virus and the risk of inflammatory bowel disease. *Reprod. Toxicol.* **11**, 647–652 (1997).
- 8.Lidar, M., Langevitz, P. & Shoenfeld, Y. The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. *Isr. Med. Assoc. J.* **11**, 558–563 (2009).
- 9.Lidar, M., Langevitz, P. & Shoenfeld, Y. The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. *Isr. Med. Assoc. J.* **11**, 558–563 (2009).
- 10.Kawashima, H. *et al.* Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. *Dig. Dis. Sci.* **45**, 723–729 (2000).
- 11.Iizuka, M. & Masamune, O. Measles vaccination and inflammatory bowel disease. *Lancet* **350**, 1775 (1997).
- 12.Iizuka, M. *et al.* Immunohistochemical analysis of the distribution of measles related antigen in the intestinal mucosa in inflammatory bowel disease. *Gut* **46**, 163–169 (2000).
- 13.Folwaczny, C. *et al.* Endothelial cell autoantibodies are a marker of disease susceptibility in inflammatory bowel disease but apparently not linked to persistent measles virus infection. *Clin. Immunol.* **95**, 197–202 (2000).
- 14.Folwaczny, C. [Viral origin of chronic inflammatory bowel diseases?]. *Z Gastroenterol* **37**, 1067–1070 (1999).
- 15.Fisher, N. C. IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus related disease? *Eur J Gastroenterol Hepatol* **10**, 355–356 (1998).
- 16.Ekbom, A. Early virus infections and inflammatory bowel disease: back to the drawing board? *Gastroenterology* **116**, 988–989 (1999).
- 17.D'Souza, Y., Dionne, S., Seidman, E. G., Bitton, A. & Ward, B. J. No evidence of persisting measles virus in the intestinal tissues of patients with inflammatory bowel disease. *Gut* **56**, 886–888 (2007).
- 18.Bernstein, C. N., Rawsthorne, P. & Blanchard, J. F. Population-based case-

control study of measles, mumps, and rubella and inflammatory bowel disease. *Inflamm. Bowel Dis.* **13**, 759–762 (2007).

19. Bernstein, C. N., Rawsthorne, P. & Blanchard, J. F. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. *Inflamm. Bowel Dis.* **13**, 759–762 (2007).

20. Afzal, M. A., Armitage, E., Ghosh, S., Williams, L. C. & Minor, P. D. Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease. *J. Med. Virol.* **62**, 377–382 (2000).

## **V2 Measles Virus and Multiple sclerosis**

1. Tselis, A. Evidence for viral etiology of multiple sclerosis. *Semin Neurol* **31**, 307–316 (2011).

2. Sips, G. J. *et al.* Involvement of morbilliviruses in the virusesis of demyelinating disease. *Rev. Med. Virol.* **17**, 223–244 (2007).

3. Rosche, B. *et al.* Measles IgG antibody index correlates with T2 lesion load on MRI in patients with early multiple sclerosis. *PLoS ONE* **7**, e28094 (2012).

4. Pekmezovic, T., Jarebinski, M. & Drulovic, J. Childhood infections as risk factors for multiple sclerosis: Belgrade case-control study. *Neuroepidemiology* **23**, 285–288 (2004).

5. Krone, B. *et al.* Common infectious agents in multiple sclerosis: a case-control study in children. *Mult. Scler.* **14**, 136–139 (2008).

6. Khaki, M. *et al.* Evaluation of viral antibodies in Iranian multiple sclerosis patients. *Neurosciences (Riyadh)* **16**, 224–228 (2011).

7. Geeraedts, F., Wilczak, N., van Binnendijk, R. & De Keyser, J. Search for morbillivirus proteins in multiple sclerosis brain tissue. *Neuroreport* **15**, 27–32 (2004).

8. Fazakerley, J. K. & Walker, R. Virus demyelination. *J. Neurovirol.* **9**, 148–164 (2003).

9. Casetta, I. & Granieri, E. Clinical infections and multiple sclerosis: contribution from analytical epidemiology. *J. Neurovirol.* **6 Suppl 2**, S147–151 (2000).

10. Brettschneider, J. *et al.* IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. *PLoS ONE* **4**, e7638 (2009).

11. Ahlgren, C., Torén, K., Odén, A. & Andersen, O. A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. *Eur. J. Epidemiol.* **24**, 541–552 (2009).

12. Ahlgren, C., Odén, A., Bergström, T. & Lycke, J. Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome. *J. Neuroimmunol.* **247**, 70–74 (2012).

## **V2 Measles Virus and Schizophrenia**

1. Vasil'eva, O. A., Kriukova, L. K. & Podoplekina, L. E. [Antibodies to measles, smallpox, influenza and arenaviruses in schizophrenic patients]. *Zh Nevropatol*



*Psikhiatr Im S S Korsakova* **86**, 106–108 (1986).

2.Rimón, R., Nishmi, M. & Halonen, P. Serum and CSF antibody levels to herpes simplex type 1, measles and rubella viruses in patients with schizophrenia. *Ann. Clin. Res.* **10**, 291–293 (1978).

3.Dickerson, F. *et al.* Antibodies to measles in individuals with recent onset psychosis. *Schizophr. Res.* **119**, 89–94 (2010).

## **V2 Measles Virus and Type 2 diabetes**

1.Lipman, T. H., Chang, Y. & Murphy, K. M. The epidemiology of type 1 diabetes in children in Philadelphia 1990-1994: evidence of an epidemic. *Diabetes Care* **25**, 1969–1975 (2002).

2.Helmke, K. *et al.* [Autoimmunity and viral infections in type-I diabetes mellitus]. *Dtsch. Med. Wochenschr.* **111**, 369–373 (1986).

3.Foy, C. A. *et al.* A search for candidate viruses in type 1 diabetic pancreas using the polymerase chain reaction. *Diabet. Med.* **11**, 564–569 (1994).

## **V2 Norwalk Virus and Inflammatory bowel disease**

1.Gump, D. *et al.* Lymphocytotoxic and microbial antibodies in Crohn's disease and matched controls. *Antonie Van Leeuwenhoek* **47**, 455–464 (1981).

2.Greenberg, H. B., Gebhard, R. L., McClain, C. J., Soltis, R. D. & Kapikian, A. Z. Antibodies to viral gastroenteritis viruses in Crohn's disease. *Gastroenterology* **76**, 349–350 (1979).

3.Gebhard, R. L. *et al.* Acute viral enteritis and exacerbations of inflammatory bowel disease. *Gastroenterology* **83**, 1207–1209 (1982).

## **V3 Herpesvirus 1, Cercopithecine and Inflammatory bowel disease**

1.Mazure, G. *et al.* Measles virus induction of human endothelial cell tissue factor procoagulant activity in vitro. *J. Gen. Virol.* **75** ( Pt 11), 2863–2871 (1994).

## **V3 Herpesvirus 1, Human and Asthma**

1.Janson, C. *et al.* The effect of infectious burden on the prevalence of atopy and respiratory allergies in Iceland, Estonia, and Sweden. *J. Allergy Clin. Immunol.* **120**, 673–679 (2007).

2.Igde, M., Igde, F. A. & Yazici, Z. Herpes simplex type I infection and atopy association in Turkish children with asthma and allergic rhinitis. *Iran J Allergy Asthma Immunol* **8**, 149–154 (2009).

## **V3 Herpesvirus 1, Human and Bipolar disorder**

1. Prasad, K. M., Watson, A. M. M., Dickerson, F. B., Yolken, R. H. & Nimgaonkar, V. L. Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. *Schizophr Bull* **38**, 1137–1148 (2012).
2. Mortensen, P. B. *et al.* Neonatal antibodies to infectious agents and risk of bipolar disorder: a population-based case-control study. *Bipolar Disord* **13**, 624–629 (2011).
3. Gerber, S. I. *et al.* Impaired functioning in euthymic patients with bipolar disorder--HSV-1 as a predictor. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **36**, 110–116 (2012).
4. Dickerson, F. B. *et al.* The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene-environmental effects in a complex human psychiatric disorder. *Bipolar Disord* **8**, 124–132 (2006).
5. Dickerson, F. B. *et al.* Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. *Biol. Psychiatry* **55**, 588–593 (2004).
6. Dickerson, F. *et al.* Association between cognitive functioning, exposure to Herpes Simplex Virus type 1, and the COMT Val158Met genetic polymorphism in adults without a psychiatric disorder. *Brain Behav. Immun.* **22**, 1103–1107 (2008).
7. Dickerson, F., Boronow, J., Stallings, C., Origoni, A. & Yolken, R. The lymphotoxin Cys13Arg polymorphism and cognitive functioning in individuals with schizophrenia. *Schizophr. Res.* **89**, 173–176 (2007).

### **V3 Herpesvirus 1, Human and Celiac disease**

1. Vesey, C. J. *et al.* Evaluation of celiac disease biopsies for adenovirus 12 DNA using a multiplex polymerase chain reaction. *Mod. Pathol.* **6**, 61–64 (1993).

### **V3 Herpesvirus 1, Human and Crohn's disease**

1. Silva, M. A. *et al.* Herpes simplex virus-1 infection of colonic explants as a model of viral-induced activation of Crohn's disease. *J Crohns Colitis* **6**, 454–463 (2012).
2. Ruther, U. *et al.* Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). *Hepatogastroenterology* **45**, 691–699 (1998).
3. François-Dufresne, A., Garbino, J., Ricou, B. & Wunderli, W. ARDS caused by herpes simplex virus pneumonia in a patient with Crohn's disease: a case report. *Intensive Care Med* **23**, 345–347 (1997).
4. Checchin, D., Buda, A., Sgarabotto, D., Sturniolo, G. C. & D' Incà, R. Successful prophylaxis with valaciclovir for relapsing HSV-1 in a girl treated with infliximab for moderate Crohn's disease. *Eur J Gastroenterol Hepatol* **21**, 1095–1096 (2009).

### **V3 Herpesvirus 1, Human and Inflammatory bowel disease**

1.Ruther, U. *et al.* Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). *Hepatology* **45**, 691–699 (1998).

### **V3 Herpesvirus 1, Human and Lung cancer**

1.Silvano, G. *et al.* A Herpes simplex virus-1 fatal encephalitis following chemo-radiotherapy, steroids and prophylactic cranial irradiation in a small cell lung cancer patient. *Lung Cancer* **57**, 243–246 (2007).

2.Sabin, A. B. & Tarro, G. Herpes simplex and herpes genitalis viruses in etiology of some human cancers. *Proc. Natl. Acad. Sci. U.S.A.* **70**, 3225–3229 (1973).

3.Massler, A. *et al.* Infant lungs are preferentially infected by adenovirus and herpes simplex virus type 1 vectors: role of the tissue mesenchymal cells. *J Gene Med* **13**, 101–113 (2011).

4.Kamiyama, H. *et al.* Herpes simplex virus-induced, death receptor-dependent apoptosis and regression of transplanted human cancers. *Cancer Sci.* **95**, 990–998 (2004).

5.Debernardis, A. *et al.* Antiviral properties of antineoplastic drugs. From herpes simplex-1 disappearance to a wide antiviral action: a serendipity case report. *Acta Biomed* **80**, 265–267 (2009).

6.Adler, H. *et al.* In the absence of T cells, natural killer cells protect from mortality due to HSV-1 encephalitis. *J. Neuroimmunol.* **93**, 208–213 (1999).

### **V3 Herpesvirus 1, Human and Major depressive disorder**

1.Garcia-Linares, M. I., Sanchez-Lorente, S., Coe, C. L. & Martinez, M. Intimate male partner violence impairs immune control over herpes simplex virus type 1 in physically and psychologically abused women. *Psychosom Med* **66**, 965–972 (2004).

2.Amsterdam, J. D. & Hernz, W. J. Serum antibodies to herpes simplex virus types I and II in depressed patients. *Biol. Psychiatry* **34**, 417–420 (1993).

### **V3 Herpesvirus 1, Human and Multiple sclerosis**

1.Active intrathecal herpes simplex virus type 1 (HSV-1) and human herpesvirus-6 (HHV-6) infection at onset of multiple sclerosis - Springer. (2013). at <<http://link.springer.com/article/10.1007%2Fs13365-012-0110-5/fulltext.html>>

2.Sanna, A. *et al.* Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1. *Mult. Scler.* **14**, 1199–1207 (2008).

3.Sanna, A. *et al.* Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1. *Mult. Scler.*

**14**, 1199–1207 (2008).

4.Ruprecht, K. *et al.* Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosis. *J. Neurovirol.* **12**, 65–71 (2006).

5.Rizzo, R. *et al.* Altered natural killer cells' response to herpes virus infection in multiple sclerosis involves KIR2DL2 expression. *J. Neuroimmunol.* **251**, 55–64 (2012).

6.Pietropaolo, V. *et al.* Detection of human herpesviruses and polyomaviruses DNA in a group of patients with relapsing-remitting multiple sclerosis. *New Microbiol.* **28**, 199–203 (2005).

7.Ordoñez, G., Pineda, B., Garcia-Navarrete, R. & Sotelo, J. Brief presence of varicella-zoster viral DNA in mononuclear cells during relapses of multiple sclerosis. *Arch. Neurol.* **61**, 529–532 (2004).

8.Kwiatkowski, A. *et al.* Herpes encephalitis during natalizumab treatment in multiple sclerosis. *Mult. Scler.* **18**, 909–911 (2012).

9.Ferrante, P. *et al.* Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack. *J. Neurovirol.* **6 Suppl 2**, S109–114 (2000).

10.Feng, Z., Zhao, R. & Wang, D. [Relationship between EB virus, Cytomegalovirus, herpes simplex virus and coxsackievirus infection and relapse of multiple sclerosis]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* **22**, 472–474 (2008).

11.Brudek, T., Lühdorf, P., Christensen, T., Hansen, H. J. & Møller-Larsen, A. Activation of endogenous retrovirus reverse transcriptase in multiple sclerosis patient lymphocytes by inactivated HSV-1, HHV-6 and VZV. *J. Neuroimmunol.* **187**, 147–155 (2007).

12.Brudek, T., Christensen, T., Hansen, H. J., Bobecka, J. & Møller-Larsen, A. Simultaneous presence of endogenous retrovirus and herpes virus antigens has profound effect on cell-mediated immune responses: implications for multiple sclerosis. *AIDS Res. Hum. Retroviruses* **20**, 415–423 (2004).

13.Brudek, T., Christensen, T., Hansen, H. J., Bobecka, J. & Møller-Larsen, A. Simultaneous presence of endogenous retrovirus and herpes virus antigens has profound effect on cell-mediated immune responses: implications for multiple sclerosis. *AIDS Res. Hum. Retroviruses* **20**, 415–423 (2004).

### **V3 Herpesvirus 1, Human and Rheumatoid arthritis**

1.Egorova, O. N., Balabanova, R. M. & Chuvirov, G. N. [Significance of antibodies to herpesviridae viruses detectable in rheumatic diseases]. *Ter. Arkh.* **70**, 41–45 (1998).

### **V3 Herpesvirus 1, Human and Schizophrenia**

1.Yolken, R. H., Torrey, E. F., Lieberman, J. A., Yang, S. & Dickerson, F. B. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. *Schizophr. Res.* **128**, 61–65

(2011).

2.Yolken, R. Viruses and schizophrenia: a focus on herpes simplex virus. *Herpes* **11 Suppl 2**, 83A–88A (2004).

3.Tedla, Y. *et al.* Serum antibodies to Toxoplasma gondii and Herpesviridae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. *Ethiop. Med. J.* **49**, 211–220 (2011).

4.Shirts, B. H. *et al.* Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia. *Schizophr. Res.* **106**, 268–274 (2008).

5.Schretlen, D. J. *et al.* Neuroanatomic and cognitive abnormalities related to herpes simplex virus type 1 in schizophrenia. *Schizophr. Res.* **118**, 224–231 (2010).

6.Prasad, K. M., Watson, A. M. M., Dickerson, F. B., Yolken, R. H. & Nimgaonkar, V. L. Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. *Schizophr Bull* **38**, 1137–1148 (2012).

7.Prasad, K. M. *et al.* Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. *Am J Psychiatry* **168**, 822–830 (2011).

8.Prasad, K. M. *et al.* Grey matter changes associated with host genetic variation and exposure to Herpes Simplex Virus 1 (HSV1) in first episode schizophrenia. *Schizophr. Res.* **118**, 232–239 (2010).

9.Prasad, K. M. R., Shirts, B. H., Yolken, R. H., Keshavan, M. S. & Nimgaonkar, V. L. Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. *Mol. Psychiatry* **12**, 105–113, 1 (2007).

10.Nimgaonkar, V. L. & Yolken, R. H. Neurotropic infectious agents and cognitive impairment in schizophrenia. *Schizophr Bull* **38**, 1135–1136 (2012).

11.Niebuhr, D. W., Millikan, A. M., Yolken, R., Li, Y. & Weber, N. S. Results from a hypothesis generating case-control study: herpes family viruses and schizophrenia among military personnel. *Schizophr Bull* **34**, 1182–1188 (2008).

12.Engel, J. A. *et al.* Neonatal herpes simplex virus type 1 brain infection affects the development of sensorimotor gating in rats. *Brain Res.* **863**, 233–240 (2000).

13.Dickerson, F. B. *et al.* Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. *Arch. Gen. Psychiatry* **60**, 466–472 (2003).

14.Dickerson, F. B. *et al.* The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene-environmental effects in a complex human psychiatric disorder. *Bipolar Disord* **8**, 124–132 (2006).

15.Dickerson, F. *et al.* Association between cognitive functioning, exposure to Herpes Simplex Virus type 1, and the COMT Val158Met genetic polymorphism in adults without a psychiatric disorder. *Brain Behav. Immun.* **22**, 1103–1107 (2008).

16.Dickerson, F. *et al.* Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. *Schizophr. Res.* **134**, 83–88 (2012).

17.Delisi, L. E. *et al.* Herpes simplex virus, cytomegalovirus and Epstein-Barr

virus antibody titres in sera from schizophrenic patients. *Psychol Med* **16**, 757–763 (1986).

18.Brown, A. S. Further evidence of infectious insults in the viruses and pathophysiology of schizophrenia. *Am J Psychiatry* **168**, 764–766 (2011).

19.Bártová, L., Rajcáni, J. & Pogády, J. Herpes simplex virus antibodies in the cerebrospinal fluid of schizophrenic patients. *Acta Virol.* **31**, 443–446 (1987).

20.Bamne, M. *et al.* Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure. *Schizophr Bull* **38**, 1149–1154 (2012).

21.Amminger, G. P. *et al.* Antibodies to infectious agents in individuals at ultra-high risk for psychosis. *Biol. Psychiatry* **61**, 1215–1217 (2007).

### **V3 Herpesvirus 1, Human and Systemic lupus erythematosus**

1.Douvas, A. & Sobelman, S. Multiple overlapping homologies between two rheumatoid antigens and immunosuppressive viruses. *Proc. Natl. Acad. Sci. U.S.A.* **88**, 6328–6332 (1991).

### **V3 Herpesvirus 1, Human and Ulcerative colitis**

1.Sýkora, J. *et al.* Adolescent herpes simplex viral infection related Ludwig's angina in ulcerative colitis. *J. Pediatr. Gastroenterol. Nutr.* **38**, 221–223 (2004).

2.Seksik, P. *et al.* Fatal herpetic hepatitis in adult following short corticotherapy: a case report. *Intensive Care Med* **25**, 415–417 (1999).

3.Ruther, U. *et al.* Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). *Hepatogastroenterology* **45**, 691–699 (1998).

4.Colemont, L. J. *et al.* Herpes simplex virus type 1 colitis: an unusual cause of diarrhea. *Am. J. Gastroenterol.* **85**, 1182–1185 (1990).

### **V3 Human Rhinovirus and Asthma**

1.Soto-Quiros, M. *et al.* High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. *J. Allergy Clin. Immunol.* **129**, 1499–1505.e5 (2012).

2.Rochlitzer, S., Hoymann, H.-G., Müller, M. & Braun, A. No exacerbation but impaired anti-viral mechanisms in a rhinovirus-chronic allergic asthma mouse model. *Clin. Sci.* (2013). doi:10.1042/CS20130174

3.Pritchard, A. L. *et al.* Innate IFNs and plasmacytoid dendritic cells constrain Th2 cytokine responses to rhinovirus: a regulatory mechanism with relevance to asthma. *J. Immunol.* **188**, 5898–5905 (2012).

4.Pritchard, A. L. *et al.* Innate IFNs and plasmacytoid dendritic cells constrain Th2 cytokine responses to rhinovirus: a regulatory mechanism with relevance to asthma. *J. Immunol.* **188**, 5898–5905 (2012).

5. Miller, E. K. *et al.* A mechanistic role for type III IFN- $\lambda$ 1 in asthma exacerbations mediated by human rhinoviruses. *Am. J. Respir. Crit. Care Med.* **185**, 508–516 (2012).
6. Miller, E. K. *et al.* A mechanistic role for type III IFN- $\lambda$ 1 in asthma exacerbations mediated by human rhinoviruses. *Am. J. Respir. Crit. Care Med.* **185**, 508–516 (2012).
7. Koponen, P., Karjalainen, M. K. & Korppi, M. IL10 polymorphisms, rhinovirus-induced bronchiolitis, and childhood asthma. *J. Allergy Clin. Immunol.* **131**, 249–250 (2013).
8. Kim, W. K. & Gern, J. E. Updates in the relationship between human rhinovirus and asthma. *Allergy Asthma Immunol Res* **4**, 116–121 (2012).
9. Kieninger, E. & Regamey, N. Rhinoviruses: markers of, or causative for, recurrent wheeze and asthma? *Eur. Respir. J.* **39**, 238–239 (2012).
10. Kennedy, J. L., Turner, R. B., Braciale, T., Heymann, P. W. & Borish, L. Pathogenesis of rhinovirus infection. *Curr Opin Virol* **2**, 287–293 (2012).
11. Kennedy, J. L., Turner, R. B., Braciale, T., Heymann, P. W. & Borish, L. Pathogenesis of rhinovirus infection. *Curr Opin Virol* **2**, 287–293 (2012).
12. James, K. M., Peebles, R. S., Jr & Hartert, T. V. Response to infections in patients with asthma and atopic disease: an epiphenomenon or reflection of host susceptibility? *J. Allergy Clin. Immunol.* **130**, 343–351 (2012).
13. Heymann, P. W. & Kennedy, J. L. Rhinovirus-induced asthma exacerbations during childhood: the importance of understanding the atopic status of the host. *J. Allergy Clin. Immunol.* **130**, 1315–1316 (2012).
14. Guibas, G. V., Makris, M. & Papadopoulos, N. G. Acute asthma exacerbations in childhood: risk factors, prevention and treatment. *Expert Rev Respir Med* **6**, 629–638 (2012).
15. Glanville, N. *et al.*  $\gamma\delta$ T cells suppress inflammation and disease during rhinovirus-induced asthma exacerbations. *Mucosal Immunol* (2013). doi:10.1038/mi.2013.3
16. Collison, A. *et al.* The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. *Nat. Med.* **19**, 232–237 (2013).
17. Çalışkan, M. *et al.* Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. *N. Engl. J. Med.* **368**, 1398–1407 (2013).
18. Beigelman, A. & Bacharier, L. B. The role of early life viral bronchiolitis in the inception of asthma. *Curr Opin Allergy Clin Immunol* **13**, 211–216 (2013).

### **V3 Human Rhinovirus and Celiac disease**

1. Kaiserlian, D., Rigal, D., Abello, J. & Revillard, J. P. Expression, function and regulation of the intercellular adhesion molecule-1 (ICAM-1) on human intestinal epithelial cell lines. *Eur. J. Immunol.* **21**, 2415–2421 (1991).

### **V3 Human Rhinovirus and Inflammatory bowel disease**

1.Kaiserlian, D., Rigal, D., Abello, J. & Revillard, J. P. Expression, function and regulation of the intercellular adhesion molecule-1 (ICAM-1) on human intestinal epithelial cell lines. *Eur. J. Immunol.* **21**, 2415–2421 (1991).

### **V3 Human Rhinovirus and Multiple sclerosis**

1.Vartdal, F., Vandvik, B. & Norrby, E. Viral and bacterial antibody responses in multiple sclerosis. *Ann. Neurol.* **8**, 248–255 (1980).

2.Simon, J., Simon, O. & Hofmann, L. [A new model of multiple sclerosis. Experimental vaccinia infection in the monkey]. *Fortschr. Med.* **98**, 1607–1611 (1980).

3.Ji, Q., Perchellet, A. & Goverman, J. M. Viral infection triggers central nervous system autoimmunity via activation of CD8+ T cells expressing dual TCRs. *Nature Immunology* **11**, 628–634 (2010).

4.Cremer, N. E., Johnson, K. P., Fein, G. & Likosky, W. H. Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and CSF antibodies by standard serologic methods. *Arch. Neurol.* **37**, 610–615 (1980).

### **V3 Human Rhinovirus and Rheumatoid arthritis**

1.Hemmer, P. [Vaccinia virus and rheumatoid arthritis]. *Bull Soc Sci Med Grand Duche Luxemb* **127**, 67–71 (1990).

2.Dlesk, A. & Panush, R. S. Viral diseases and arthritis. *Compr Ther* **13**, 13–17 (1987).

3.Brooks, P., Readett, M. & Kirov, S. Rheumatoid arthritis and generalized vaccinia. *JAMA* **239**, 747–748 (1978).

### **V3 Vaccinia Virus and Multiple sclerosis**

1.Vartdal, F., Vandvik, B. & Norrby, E. Viral and bacterial antibody responses in multiple sclerosis. *Ann. Neurol.* **8**, 248–255 (1980).

2.Simon, J., Simon, O. & Hofmann, L. [A new model of multiple sclerosis. Experimental vaccinia infection in the monkey]. *Fortschr. Med.* **98**, 1607–1611 (1980).

3.Ji, Q., Perchellet, A. & Goverman, J. M. Viral infection triggers central nervous system autoimmunity via activation of CD8+ T cells expressing dual TCRs. *Nature Immunology* **11**, 628–634 (2010).

4.Cremer, N. E., Johnson, K. P., Fein, G. & Likosky, W. H. Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and CSF antibodies by standard serologic methods. *Arch. Neurol.* **37**, 610–615 (1980).

### **V3 Vaccinia Virus and Schizophrenia**



1.Pert, C. B., Knight, J. G., Laing, P. & Markwell, M. A. Scenarios for a viral etiology of schizophrenia. *Schizophr Bull* **14**, 243–247 (1988).

2.Albrecht, P., Torrey, E. F., Boone, E., Hicks, J. T. & Daniel, N. Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients. *Lancet* **2**, 769–772 (1980).

#### **V4 Dengue Virus and Coronary heart disease**

1.Obeyesekere, I. & Hermon, Y. Myocarditis and cardiomyopathy after arbovirus infections (dengue and chikungunya fever). *Br Heart J* **34**, 821–827 (1972).

#### **V4 Dengue Virus and Schizophrenia**

1.Shaskan, E. G., Peszke, M. A. & Niederman, J. C. Studies of platelet monoamine oxidase activity in Epstein-Barr and dengue virus infections. *Schizophr Bull* **6**, 347–354 (1980).

#### **V4 Dengue Virus and Type 2 diabetes**

1.Pang, J. *et al.* Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study. *PLoS Negl Trop Dis* **6**, e1641 (2012).

2.Lee, M.-S., Hwang, K.-P., Chen, T.-C., Lu, P.-L. & Chen, T.-P. Clinical characteristics of dengue and dengue hemorrhagic fever in a medical center of southern Taiwan during the 2002 epidemic. *J Microbiol Immunol Infect* **39**, 121–129 (2006).

#### **V4 Hepatitis B Virus and Alcohol dependence**

1.Zani, C. *et al.* The epidemiological pattern of chronic liver diseases in a cluster undergoing voluntary screening for hepatitis B and C. *Dig Liver Dis* **43**, 653–658 (2011).

2.Yotsuyanagi, H. *et al.* Role of hepatitis B virus in hepatocarcinogenesis in alcoholics. *Alcohol. Clin. Exp. Res.* **28**, 181S–185S (2004).

3.Xiang, G.-Q., Meng, X.-D. & He, X.-H. [Research on prognosis of liver cirrhosis patients with hepatitis B virus infection superimposed on alcoholic liver disease]. *Zhonghua Gan Zang Bing Za Zhi* **17**, 72–73 (2009).

4.Park, C.-H. *et al.* Family history influences the early onset of hepatocellular carcinoma. *World J. Gastroenterol.* **18**, 2661–2667 (2012).

5.Oliveira, L. C. M. de, Silva, T. E. da & Alves, M. H. [Response to hepatitis B vaccine in alcoholics without clinically evident liver cirrhosis]. *Arq Gastroenterol* **44**, 195–200 (2007).

6.Mota, A., Guedes, F., Areias, J., Pinho, L. & Cardoso, M. F. Alcohol

consumption among patients with hepatitis B infection in northern Portugal considering gender and hepatitis B virus genotype differences. *Alcohol* **44**, 149–156 (2010).

7.Martínez-Raga, J. *et al.* Hepatitis B and C in alcohol-dependent patients admitted to a UK alcohol inpatient treatment unit. *Addict Biol* **6**, 363–372 (2001).

8.Makarov, V. K. [The effect of alcohol on serum lipid composition in hepatitis B virus carriers]. *Gig Sanit* 38–40 (2003).

9.Lin, C.-W. *et al.* Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. *J. Hepatol.* **58**, 730–735 (2013).

10.Gitto, S., Micco, L., Conti, F., Andreone, P. & Bernardi, M. Alcohol and viral hepatitis: a mini-review. *Dig Liver Dis* **41**, 67–70 (2009).

11.Gao, B. Interaction of alcohol and hepatitis viral proteins: implication in synergistic effect of alcohol drinking and viral hepatitis on liver injury. *Alcohol* **27**, 69–72 (2002).

12.De Oliveira, L. C. *et al.* Prevalence of hepatitis B and hepatitis C markers in alcoholics with and without clinically evident hepatic cirrhosis. *Rev. Inst. Med. Trop. Sao Paulo* **41**, 69–73 (1999).

13.Curcio, F. *et al.* Epidemiological survey of hepatitis C virus infection in a cohort of patients from a ser.T in Naples, Italy. *J Addict Med* **5**, 43–49 (2011).

14.Couzigou, P. *et al.* [Alcohol, steatohepatitis, insulin resistance and hepatitis C]. *Gastroenterol. Clin. Biol.* **32**, S74–81 (2008).

15.Christou, L., Kalambokis, G. & Tsianos, E. V. Weil's disease in a patient with chronic viral hepatitis and history of alcohol abuse. *Intern. Med.* **47**, 933–937 (2008).

16.Chou, A.-L., Huang, W.-W., Tsao, S.-M., Li, C.-T. & Su, C.-C. Human herpesvirus type 8 in patients with cirrhosis: correlation with sex, alcoholism, hepatitis B virus, disease severity, and thrombocytopenia. *Am. J. Clin. Pathol.* **130**, 231–237 (2008).

17.Abdel-Hamid, N. M. Recent insights on risk factors of hepatocellular carcinoma. *World J Hepatol* **1**, 3–7 (2009).

## **V4 Hepatitis B Virus and Bipolar disorder**

1.Baillargeon, J. G. *et al.* Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting. *AIDS Care* **20**, 124–129 (2008).

## **V4 Hepatitis B Virus and Breast cancer**

1.Yeo, W. *et al.* Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. *Br. J. Cancer* **90**, 1306–1311 (2004).

2.Su, F.-H. *et al.* Association between chronic viral hepatitis infection and breast cancer risk: a nationwide population-based case-control study. *BMC Cancer* **11**, 495 (2011).

3.Sohn, B. S. *et al.* Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine. *Jpn. J. Clin. Oncol.* **41**, 1059–1066 (2011).

4.Shoushtari, A. H. & Shaw, R. A. Fulminant hepatitis following chemotherapy treatment for breast cancer. *BMJ Case Rep* **2013**, (2013).

5.Liu, Y. *et al.* Hepatitis B virus X protein stabilizes amplified in breast cancer 1 protein and cooperates with it to promote human hepatocellular carcinoma cell invasiveness. *Hepatology* **56**, 1015–1024 (2012).

6.Lee, H. J. *et al.* Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy. *Breast Cancer* (2012). doi:10.1007/s12282-012-0417-3

7.Hirsch, I., Caux, C., Hasan, U., Bendriss-Vermare, N. & Olive, D. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. *Trends in Immunology* **31**, 391–397 (2010).

8.Borde, J. P. *et al.* [Hepatitis B reactivation following immunosuppressive therapy and screening adherence: a neglected problem?]. *Dtsch. Med. Wochenschr.* **137**, 1458–1462 (2012).

## **V4 Hepatitis B Virus and Chronic lymphocytic leukemia**

1.Yağci, M. *et al.* Hepatitis B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. *Hematology* **15**, 240–244 (2010).

2.Rossi, D. *et al.* Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia. *Leuk. Lymphoma* **50**, 604–611 (2009).

3.Pinato, D. J. *et al.* Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship. *Dig Liver Dis* **44**, 235–238 (2012).

4.Molagic, V. *et al.* Preliminary data on the involvement of B, C and D hepatitis viruses in the etiogenesis of chronic lymphoproliferative syndromes in Romania. *Rom J Intern Med* **47**, 25–34 (2009).

5.Lim, S. M. *et al.* [Hepatitis B virus reactivation during chlorambucil and prednisolone treatment in an HBsAg-negative and anti-HBs-positive patient with B-cell chronic lymphocytic leukemia]. *Korean J Hepatol* **14**, 213–218 (2008).

6.Franceschini, R., Cataldi, A., Tenconi, G. L., Icardi, G. & Bruzzone, B. M. Reactivation of hepatitis B virus infection during cytotoxic chemotherapy. *Am. J. Gastroenterol.* **96**, 606–607 (2001).

7.Becker, N. *et al.* Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph. *J. Cancer Res. Clin. Oncol.* **138**, 1993–2001 (2012).

## **V4 Hepatitis B Virus and Crohn's disease**

1.Ueno, Y. *et al.* Infliximab therapy for Crohn's disease in a patient with chronic

hepatitis B. *Dig. Dis. Sci.* **50**, 163–166 (2005).

2.Papa, A. *et al.* Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- $\alpha$  agents. *J Crohns Colitis* **7**, 113–119 (2013).

3.Ojiro, K. *et al.* Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. *J. Gastroenterol.* **43**, 397–401 (2008).

4.Morisco, F. *et al.* Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. *J. Viral Hepat.* **20**, 200–208 (2013).

5.Loras, C. *et al.* Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. *Gut* **59**, 1340–1346 (2010).

6.Lidar, M. *et al.* Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true virusic role. *Ann. N. Y. Acad. Sci.* **1173**, 640–648 (2009).

7.Fuchs, I., Abu-Shakra, M. & Sikuler, E. Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations. *Isr. Med. Assoc. J.* **15**, 303–307 (2013).

8.Esteve, M. *et al.* Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. *Gut* **53**, 1363–1365 (2004).

9.Biancone, L. *et al.* Hepatitis B and C virus infection in Crohn's disease. *Inflamm. Bowel Dis.* **7**, 287–294 (2001).

## **V4 Hepatitis B Virus and Inflammatory bowel disease**

1.Tolentino, Y. F. M., Fogaca, H. S., Zaltman, C., Ximenes, L. L. L. & Coelho, H. S. M. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital. *World J. Gastroenterol.* **14**, 3201–3206 (2008).

2.Shouval, D. & Shibolet, O. Immunosuppression and HBV reactivation. *Semin. Liver Dis.* **33**, 167–177 (2013).

3.Shale, M. J. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. *Br. Med. Bull.* **92**, 61–77 (2009).

4.Sempere, L. *et al.* Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. *Vaccine* **31**, 3065–3071 (2013).

5.Poupardin, C. *et al.* Hepatitis B reactivation in patients with inflammatory bowel disease: A prospective survey on screening and prevention practices at general hospitals in France. *Inflamm. Bowel Dis.* **17**, 669–670 (2011).

6.Papa, A. *et al.* Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- $\alpha$  agents. *J Crohns Colitis* **7**, 113–119 (2013).

7.Morisco, F. *et al.* Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. *Dig Liver Dis* **43 Suppl 1**, S40–48 (2011).

8.Morisco, F. *et al.* Effect of immunosuppressive therapy on patients with

inflammatory bowel diseases and hepatitis B or C virus infection. *J. Viral Hepat.* **20**, 200–208 (2013).

9. Millonig, G., Kern, M., Ludwiczek, O., Nachbaur, K. & Vogel, W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? *World J. Gastroenterol.* **12**, 974–976 (2006).

10. Loras, C. *et al.* Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. *Gut* **59**, 1340–1346 (2010).

11. López-Serrano, P., Pérez-Calle, J. L. & Sánchez-Tembleque, M. D. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. *World J. Gastroenterol.* **19**, 1342–1348 (2013).

12. Hou, J. K., Velayos, F., Terrault, N. & Mahadevan, U. Viral hepatitis and inflammatory bowel disease. *Inflamm. Bowel Dis.* **16**, 925–932 (2010).

13. Hou, J. K., Velayos, F., Terrault, N. & Mahadevan, U. Viral hepatitis and inflammatory bowel disease. *Inflamm. Bowel Dis.* **16**, 925–932 (2010).

14. Gisbert, J. P. *et al.* Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. *Aliment. Pharmacol. Ther.* **35**, 1379–1385 (2012).

15. Fuchs, I., Abu-Shakra, M. & Sikuler, E. Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations. *Isr. Med. Assoc. J.* **15**, 303–307 (2013).

16. Chevaux, J.-B. *et al.* Inflammatory bowel disease and hepatitis B and C. *Gastroenterol. Clin. Biol.* **33**, 1082–1093 (2009).

17. Biancone, L. *et al.* Hepatitis B and C virus infection in Crohn's disease. *Inflamm. Bowel Dis.* **7**, 287–294 (2001).

## **V4 Hepatitis B Virus and Multiple sclerosis**

1. Ram, M. *et al.* The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. *Autoimmun Rev* **7**, 621–625 (2008).

2. Maya, R., Gershwin, M. E. & Shoenfeld, Y. Hepatitis B virus (HBV) and autoimmune disease. *Clin Rev Allergy Immunol* **34**, 85–102 (2008).

3. Martyn, C. N. Childhood infection and adult disease. *Ciba Found. Symp.* **156**, 93–102; discussion 102–108 (1991).

4. Geier, D. A. & Geier, M. R. A case-control study of serious autoimmune adverse events following hepatitis B immunization. *Autoimmunity* **38**, 295–301 (2005).

5. Bogdanos, D.-P. *et al.* A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. *Clin. Dev. Immunol.* **12**, 217–224 (2005).

## **V4 Hepatitis B Virus and Schizophrenia**

1. Said, W. M., Saleh, R. & Jumaian, N. Prevalence of hepatitis B virus among

chronic schizophrenia patients. *East. Mediterr. Health J.* **7**, 526–530 (2001).

2.Libíková, H., Pogády, J., Stanček, D. & Mucha, V. Hepatitis B and herpes viral components in the cerebrospinal fluid of chronic schizophrenic and senile demented patients. *Acta Virol.* **25**, 182–190 (1981).

3.Hung, C.-C. *et al.* Prevalence of hepatitis B and hepatitis C in patients with chronic schizophrenia living in institutions. *J Chin Med Assoc* **75**, 275–280 (2012).

4.Chaudhury, S., Chandra, S. & Augustine, M. Prevalence of Australia antigen (HBsAg) in institutionalised patients with psychosis. *Br J Psychiatry* **164**, 542–543 (1994).

## **V4 Hepatitis B Virus and Type 2 diabetes**

1.Yang, X. *et al.* Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes. *Endocr. Relat. Cancer* **20**, 161–171 (2013).

2.Soverini, V. *et al.* HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. *Acta Diabetol* **48**, 337–343 (2011).

3.Imazeki, F. *et al.* Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. *Liver Int.* **28**, 355–362 (2008).

4.Huang, Z.-S. *et al.* Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: a ten-year observation. *J. Gastroenterol. Hepatol.* **25**, 1420–1425 (2010).

5.Demir, M. *et al.* The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. *Eur J Gastroenterol Hepatol* **20**, 668–673 (2008).

6.Cheng, A. Y. S. *et al.* Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. *Diabetologia* **49**, 1777–1784 (2006).

7.Akbar, D. H., Siddique, A. M. & Ahmed, M. M. Prevalence of Type-2 diabetes in patients with hepatitis C and B virus infection in Jeddah, Saudi Arabia. *Med Princ Pract* **11**, 82–85 (2002).

## **V4 Hepatitis B Virus and Ulcerative colitis**

1.Park, S. H. *et al.* Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. *Inflamm. Bowel Dis.* **18**, 2004–2010 (2012).

2.Papa, A. *et al.* Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- $\alpha$  agents. *J Crohns Colitis* **7**, 113–119 (2013).

3.Morisco, F. *et al.* Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. *J. Viral Hepat.* **20**, 200–208 (2013).

4.Lidar, M. *et al.* Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true virusic role. *Ann. N. Y. Acad. Sci.* **1173**, 640–648 (2009).

5.Biancone, L. *et al.* Hepatitis B and C virus infection in Crohn's disease. *Inflamm. Bowel Dis.* **7**, 287–294 (2001).

#### **V4 Hepatitis C Virus and Alcohol dependence**

1.Novo-Veleiro, I. *et al.* Prevalence of Hepatitis C Virus Infection in Alcoholic Patients: Cohort Study and Systematic Review. *Alcohol Alcohol.* (2013). doi:10.1093/alcalc/agt044

2.Machida, K. TLRs, Alcohol, HCV, and Tumorigenesis. *Gastroenterol Res Pract* **2010**, 518674 (2010).

3.Jackson, C. B. *et al.* Identification of substance use and dependence among patients with viral hepatitis. *Dig Liver Dis* **42**, 650–656 (2010).

4.Innes, H. A. *et al.* Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. *Hepatology* **57**, 451–460 (2013).

5.Gitto, S., Micco, L., Conti, F., Andreone, P. & Bernardi, M. Alcohol and viral hepatitis: a mini-review. *Dig Liver Dis* **41**, 67–70 (2009).

#### **V4 Hepatitis C Virus and Bipolar disorder**

1.Rifai, M. A. Hepatitis C treatment of patients with bipolar disorder: a case series. *Prim Care Companion J Clin Psychiatry* **8**, 361–366 (2006).

2.Himelhoch, S. *et al.* Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. *Psychosomatics* **50**, 30–37 (2009).

3.Fuller, B. E. *et al.* Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. *Gen Hosp Psychiatry* **33**, 232–237 (2011).

4.el-Serag, H. B., Kunik, M., Richardson, P. & Rabeneck, L. Psychiatric disorders among veterans with hepatitis C infection. *Gastroenterology* **123**, 476–482 (2002).

#### **V4 Hepatitis C Virus and Breast cancer**

1.Yamac, D. *et al.* Polymyositis and hepatitis concurrent with breast cancer. *Med Princ Pract* **13**, 171–175 (2004).

2.Su, F.-H. *et al.* Association between chronic viral hepatitis infection and breast cancer risk: a nationwide population-based case-control study. *BMC Cancer* **11**, 495 (2011).

3.Miura, Y. *et al.* The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. *J Cancer* **4**, 519–523 (2013).

4.Larrey, D., Bozonnat, M.-C., Kain, I., Pageaux, G.-P. & Assenat, E. Is chronic hepatitis C virus infection a risk factor for breast cancer? *World J. Gastroenterol.* **16**, 3687–3691 (2010).

5.D'Angelo, S., Deutscher, M., Dickler, M. & Weinstock, D. M. Hepatitis C virus

infection does not preclude standard breast cancer-directed therapy. *Clin. Breast Cancer* **9**, 51–52 (2009).

#### **V4 Hepatitis C Virus and Chronic lymphocytic leukemia**

1. Sonmez, M. *et al.* The relation of lymphoma and hepatitis B virus/hepatitis C virus infections in the region of East Black Sea, Turkey. *Tumori* **93**, 536–539 (2007).
2. Schöllkopf, C. *et al.* Hepatitis C infection and risk of malignant lymphoma. *Int. J. Cancer* **122**, 1885–1890 (2008).
3. Realdon, S. *et al.* High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. *J. Hepatol.* **34**, 723–729 (2001).
4. Ramos, C. A. *et al.* Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. *Haematologica* **94**, 249–257 (2009).
5. Nieters, A. *et al.* Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. *Gastroenterology* **131**, 1879–1886 (2006).
6. Nicolosi Guidicelli, S. *et al.* Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group. *Hematol Oncol* **30**, 137–142 (2012).
7. Molagic, V. *et al.* Preliminary data on the involvement of B, C and D hepatitis viruses in the etioviruses of chronic lymphoproliferative syndromes in Romania. *Rom J Intern Med* **47**, 25–34 (2009).
8. Gharagozloo, S., Khoshnoodi, J. & Shokri, F. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia, multiple myeloma and chronic lymphocytic leukemia. *Pathol. Oncol. Res.* **7**, 135–139 (2001).
9. Fazi, C. *et al.* Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. *Cytometry B Clin Cytom* **78 Suppl 1**, S61–68 (2010).
10. Farahani, M. *et al.* Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. *J. Med. Virol.* **85**, 235–240 (2013).
11. Becker, D. J., Sevilla, D. W. & O'Connor, O. Concurrent and apposed hepatocellular carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in a patient with hepatitis C virus. *Acta Haematol.* **123**, 77–80 (2010).
12. Bachy, E., Besson, C., Suarez, F. & Hermine, O. Hepatitis C virus infection and lymphoma. *Mediterr J Hematol Infect Dis* **2**, e2010004 (2010).
13. Anoop, P., Wotherspoon, A. & Matutes, E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. *Br. J. Haematol.* **148**, 484–486 (2010).

#### **V4 Hepatitis C Virus and Coronary heart disease**

1. Vassalle, C., Masini, S., Bianchi, F. & Zucchelli, G. C. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. *Heart* **90**, 565–



566 (2004).

2.Tsui, J. I. *et al.* Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. *J. Card. Fail.* **15**, 451–456 (2009).

3.Roed, T., Lebech, A.-M., Kjaer, A. & Weis, N. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. *Clin Physiol Funct Imaging* **32**, 421–430 (2012).

4.Haji, S. A. *et al.* Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. *J. Heart Lung Transplant.* **23**, 277–283 (2004).

5.Freiberg, M. S. *et al.* The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. *Circ Cardiovasc Qual Outcomes* **4**, 425–432 (2011).

6.Corey, K. E. *et al.* Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. *Hepatology* **50**, 1030–1037 (2009).

7.Butt, A. A. *et al.* Hepatitis C virus infection and the risk of coronary disease. *Clin. Infect. Dis.* **49**, 225–232 (2009).

8.Alyan, O. *et al.* Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. *Circ. J.* **72**, 1960–1965 (2008).

## **V4 Hepatitis C Virus and Crohn's disease**

1.Loras, C. *et al.* Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. *Gut* **59**, 1340–1346 (2010).

2.Longo, F. *et al.* [Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors]. *Gastroenterol. Clin. Biol.* **24**, 77–81 (2000).

3.Khalil, A., Lucidarme, D., Desurmont, P., Hamdan-Khalil, R. & Filoche, B. [Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C]. *Gastroenterol. Clin. Biol.* **29**, 193–196 (2005).

4.Biancone, L. *et al.* Hepatitis B and C virus infection in Crohn's disease. *Inflamm. Bowel Dis.* **7**, 287–294 (2001).

## **V4 Hepatitis C Virus and Inflammatory bowel disease**

1.Loras, C. *et al.* Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. *Gut* **59**, 1340–1346 (2010).

2.Longo, F. *et al.* [Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors]. *Gastroenterol. Clin. Biol.* **24**, 77–81 (2000).

3.Khalil, A., Lucidarme, D., Desurmont, P., Hamdan-Khalil, R. & Filoche, B.

[Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C]. *Gastroenterol. Clin. Biol.* **29**, 193–196 (2005).

4.Biancone, L. *et al.* Hepatitis B and C virus infection in Crohn's disease. *Inflamm. Bowel Dis.* **7**, 287–294 (2001).

#### **V4 Hepatitis C Virus and Multiple sclerosis**

1.Obermayer-Straub, P. & Manns, M. P. Hepatitis C and D, retroviruses and autoimmune manifestations. *J. Autoimmun.* **16**, 275–285 (2001).

2.Höftberger, R. *et al.* Fulminant central nervous system demyelination associated with interferon-alpha therapy and hepatitis C virus infection. *Mult. Scler.* **13**, 1100–1106 (2007).

3.Funaoka, M. *et al.* Fulminant hepatitis caused by hepatitis C virus during treatment for multiple sclerosis. *J. Gastroenterol.* **31**, 119–122 (1996).

4.Fortunato, G. *et al.* Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. *J. Interferon Cytokine Res.* **28**, 141–152 (2008).

#### **V4 Hepatitis C Virus and Schizophrenia**

1.Nakamura, Y. *et al.* High prevalence of the hepatitis C virus infection among the inpatients of schizophrenia and psychoactive substance abuse in Japan. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **28**, 591–597 (2004).

2.Hung, C.-C. *et al.* Prevalence of hepatitis B and hepatitis C in patients with chronic schizophrenia living in institutions. *J Chin Med Assoc* **75**, 275–280 (2012).

3.Huckans, M. *et al.* The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. *Antivir. Ther. (Lond.)* **15**, 111–119 (2010).

4.Himelhoch, S. *et al.* Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. *Psychosomatics* **50**, 30–37 (2009).

5.Fuller, B. E. *et al.* Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. *Gen Hosp Psychiatry* **33**, 232–237 (2011).

6.Freudenreich, O., Gandhi, R. T., Walsh, J. P., Henderson, D. C. & Goff, D. C. Hepatitis C in schizophrenia: screening experience in a cluster-dwelling clozapine cohort. *Psychosomatics* **48**, 405–411 (2007).

7.Cournos, F., McKinnon, K. & Sullivan, G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. *J Clin Psychiatry* **66 Suppl 6**, 27–33 (2005).

8.Baillargeon, J. G. *et al.* Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting. *AIDS Care* **20**, 124–129 (2008).

#### **V4 Hepatitis C Virus and Type 2 diabetes**

1. Wu, Y., Ahmed, A. & Kamal, A. Donor diabetes mellitus is an independent risk factor for graft loss in HCV positive but not HCV negative liver transplant recipients. *Dig. Dis. Sci.* **58**, 574–578 (2013).
2. Wang, Q., Chen, J., Wang, Y., Han, X. & Chen, X. Hepatitis C virus induced a novel apoptosis-like death of pancreatic beta cells through a caspase 3-dependent pathway. *PLoS ONE* **7**, e38522 (2012).
3. Wang, C. *et al.* Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. *Int. J. Cancer* **130**, 1639–1648 (2012).
4. Skowroński, M., Zozulińska-Ziółkiewicz, D., Juszczak, J., Michalski, W. & Wierusz-Wysocka, B. C-reactive protein and chronic hepatitis C virus infection in diabetic patients. *Pol. Arch. Med. Wewn.* **120**, 491–496 (2010).
5. Shoji, I., Deng, L. & Hotta, H. Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders. *Front Microbiol* **2**, 278 (2011).
6. Sayed-Ahmed, L., Kotb, N., El-Serogy, H., El-Shazly, S. & Eid, M. TNF-alpha and CXCL-10 correlation with insulin resistance in patients with chronic hepatitis C virus infection. *Egypt J Immunol* **17**, 101–111 (2010).
7. Samantray, J., Zambare, S., Seyoum, B. & Abou-Samra, A. B. Glucose control and lipid metabolism in African American patients with type 2 diabetes mellitus and chronic hepatitis C viral infection. *Endocr Pract* **17**, 363–368 (2011).
8. Rouabhia, S. *et al.* Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection. *World J. Gastroenterol.* **16**, 3427–3431 (2010).
9. Parvaiz, F. *et al.* Hepatitis C virus infection: molecular pathways to insulin resistance. *Virol. J.* **8**, 474 (2011).
10. Naing, C., Mak, J. W., Wai, N. & Maung, M. Diabetes and infections-hepatitis C: is there type 2 diabetes excess in hepatitis C infection? *Curr. Diab. Rep.* **13**, 428–434 (2013).
11. Naing, C., Mak, J. W., Ahmed, S. I. & Maung, M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. *World J. Gastroenterol.* **18**, 1642–1651 (2012).
12. Montenegro, L., De Michina, A., Misciagna, G., Guerra, V. & Di Leo, A. Virus C hepatitis and type 2 diabetes: a cohort study in southern Italy. *Am. J. Gastroenterol.* **108**, 1108–1111 (2013).
13. Mihm, S. Hepatitis C virus, diabetes and steatosis: clinical evidence in favor of a linkage and role of genotypes. *Dig Dis* **28**, 280–284 (2010).
14. Liu, J.-L. *et al.* Community-based cross-sectional study: the association of lipids with hepatitis C seropositivity and diabetes mellitus. *J. Gastroenterol. Hepatol.* **27**, 1688–1694 (2012).
15. Kobashi-Margáin, R. A., Gutiérrez-Grobe, Y., Ponciano-Rodríguez, G., Uribe, M. & Méndez-Sánchez, N. Prevalence of type 2 diabetes mellitus and chronic liver disease: a retrospective study of the association of two increasingly common diseases in Mexico. *Ann Hepatol* **9**, 282–288 (2010).
16. Jadoon, N. A., Shahzad, M. A., Yaqoob, R., Hussain, M. & Ali, N. Seroprevalence of hepatitis C in type 2 diabetes: evidence for a positive association.

*Virol. J.* **7**, 304 (2010).

17.Iwasa, M. *et al.* Visceral fat volume predicts new-onset type 2 diabetes in patients with chronic hepatitis C. *Diabetes Res. Clin. Pract.* **94**, 468–470 (2011).

18.Hung, C.-H. *et al.* Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. *World J. Gastroenterol.* **16**, 2265–2271 (2010).

19.Hung, C.-H. *et al.* Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. *Int. J. Cancer* **128**, 2344–2352 (2011).

20.Hung, C.-H. *et al.* Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. *Liver Int.* **29**, 1086–1093 (2009).

21.Huang, J.-F., Yu, M.-L., Dai, C.-Y. & Chuang, W.-L. Glucose abnormalities in hepatitis C virus infection. *Kaohsiung J. Med. Sci.* **29**, 61–68 (2013).

22.Himoto, T. *et al.* The ratio of insulin-like growth factor-I/insulin-like growth factor-binding protein-3 in sera of patients with hepatitis C virus-related chronic liver disease as a predictive marker of insulin resistance. *Nutr Res* **33**, 27–33 (2013).

23.Greca, L. F., Pinto, L. C., Rados, D. R., Canani, L. H. & Gross, J. L. Clinical features of patients with type 2 diabetes mellitus and hepatitis C infection. *Braz. J. Med. Biol. Res.* **45**, 284–290 (2012).

24.Giordanino, C. *et al.* Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study. *Dig Liver Dis* **44**, 406–412 (2012).

25.Elhawary, E. I. *et al.* Association of HCV with diabetes mellitus: an Egyptian case-control study. *Virol. J.* **8**, 367 (2011).

26.Deng, L. *et al.* Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. *J. Virol.* **85**, 8556–8568 (2011).

27.Chehadeh, W. *et al.* Hepatitis C virus infection in a population with high incidence of type 2 diabetes: impact on diabetes complications. *J Infect Public Health* **4**, 200–206 (2011).

28.Bose, S. K., Shrivastava, S., Meyer, K., Ray, R. B. & Ray, R. Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. *J. Virol.* **86**, 6315–6322 (2012).

29.Badar, S. *et al.* Association of hepatitis C virus with insulin resistance: evidences from animal studies and clinical studies. *Hepat Mon* **12**, 11–15 (2012).

30.Arase, Y. *et al.* Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. *Hepatology* **57**, 964–973 (2013).

31.Amarapurkar, D. N. & Patel, N. D. Increased prevalence of type II diabetes mellitus in hepatitis C virus infection in western India. *Trop Gastroenterol* **29**, 148–152 (2008).

32.Amarapurkar, D. N. & Patel, N. D. Increased prevalence of type II diabetes mellitus in hepatitis C virus infection in western India. *Trop Gastroenterol* **29**, 148–152 (2008).

33. Alberstein, M., Zornitzki, T., Zick, Y. & Knobler, H. Hepatitis C core protein impairs insulin downstream signalling and regulatory role of IGFBP-1 expression. *J. Viral Hepat.* **19**, 65–71 (2012).

34. Adegoke, O. A. *et al.* Seroprevalence of hepatitis C virus infection in Nigerians with type 2 diabetes mellitus. *Niger J Clin Pract* **11**, 199–201 (2008).

## **V4 Hepatitis C Virus and Ulcerative colitis**

1. Papa, A. *et al.* Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- $\alpha$  agents. *J Crohns Colitis* **7**, 113–119 (2013).

2. Morisco, F. *et al.* Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. *J. Viral Hepat.* **20**, 200–208 (2013).

3. Loras, C. *et al.* Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. *Gut* **59**, 1340–1346 (2010).

4. Longo, F. *et al.* [Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors]. *Gastroenterol. Clin. Biol.* **24**, 77–81 (2000).

5. Longo, F. *et al.* [Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors]. *Gastroenterol. Clin. Biol.* **24**, 77–81 (2000).

6. Lin, M. V., Blonski, W., Buchner, A. M., Reddy, K. R. & Lichtenstein, G. R. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. *Dig. Dis. Sci.* **58**, 1149–1156 (2013).

7. Lidar, M. *et al.* Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true virusic role. *Ann. N. Y. Acad. Sci.* **1173**, 640–648 (2009).

8. Lidar, M. *et al.* Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true virusic role. *Ann. N. Y. Acad. Sci.* **1173**, 640–648 (2009).

9. Li, Y.-D., Lin, J.-J. & Zheng, S.-S. Inflammatory bowel diseases and hepatitis C virus infection. *HBPD INT* **9**, 398–401 (2010).

10. Khalil, A., Lucidarme, D., Desurmont, P., Hamdan-Khalil, R. & Filoche, B. [Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C]. *Gastroenterol. Clin. Biol.* **29**, 193–196 (2005).

11. Horn, T. L., Reynolds, J., de Villiers, W. & Peña, L. R. Hepatitis C virus and inflammatory bowel disease. *Dig. Dis. Sci.* **54**, 1171–1177 (2009).

12. Gisbert, J. P., Chaparro, M. & Esteve, M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. *Aliment. Pharmacol. Ther.* **33**, 619–633 (2011).

13. Esteve, M. *et al.* Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. *Gut* **53**, 1363–1365 (2004).

14. Chevaux, J.-B. *et al.* Inflammatory bowel disease and hepatitis B and C. *Gastroenterol. Clin. Biol.* **33**, 1082–1093 (2009).

15.Biancone, L. *et al.* Hepatitis B and C virus infection in Crohn's disease. *Inflamm. Bowel Dis.* **7**, 287–294 (2001).

## **V4 Human Immunodeficiency Virus and Alcohol dependence**

1.Tsui, J. I. *et al.* Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C. *J Stud Alcohol Drugs* **74**, 266–270 (2013).

2.Schulte, T., Müller-Oehring, E. M., Sullivan, E. V. & Pfefferbaum, A. White matter fiber compromise contributes differentially to attention and emotion processing impairment in alcoholism, HIV-infection, and their comorbidity. *Neuropsychologia* **50**, 2812–2822 (2012).

3.Sassoon, S. A., Rosenbloom, M. J., Fama, R., Sullivan, E. V. & Pfefferbaum, A. Selective neurocognitive deficits and poor life functioning are associated with significant depressive symptoms in alcoholism-HIV infection comorbidity. *Psychiatry Res* **199**, 102–110 (2012).

4.Pfefferbaum, A. *et al.* Regional brain structural dysmorphology in human immunodeficiency virus infection: effects of acquired immune deficiency syndrome, alcoholism, and age. *Biol. Psychiatry* **72**, 361–370 (2012).

5.McGinnis, K. A. *et al.* Comparing alcohol screening measures among HIV-infected and -uninfected men. *Alcohol. Clin. Exp. Res.* **37**, 435–442 (2013).

6.McCance-Katz, E. F. *et al.* Untreated HIV infection is associated with higher blood alcohol levels. *J. Acquir. Immune Defic. Syndr.* **60**, 282–288 (2012).

7.Malow, R. M. *et al.* Neurological function, information-motivation-behavioral skills factors, and risk behaviors among HIV-positive alcohol users. *AIDS Behav* **16**, 2297–2308 (2012).

8.Longmire-Avital, B., Holder, C. A., Golub, S. A. & Parsons, J. T. Risk factors for drinking among HIV-positive African American adults: the depression-gender interaction. *Am J Drug Alcohol Abuse* **38**, 260–266 (2012).

9.Lima, V. D. *et al.* The effect of history of injection drug use and alcoholism on HIV disease progression. *AIDS Care* (2013). doi:10.1080/09540121.2013.804900

10.Kermode, M., Sono, C. Z., Songput, C. H. & Devine, A. Falling through the cracks: a qualitative study of HIV risks among women who use drugs and alcohol in Northeast India. *BMC Int Health Hum Rights* **13**, 9 (2013).

11.Hormes, J. M., Gerhardstein, K. R. & Griffin, P. T. Under-reporting of alcohol and substance use versus other psychiatric symptoms in individuals living with HIV. *AIDS Care* **24**, 420–423 (2012).

12.Holmes, J. M., Gerhardstein, K. R. & Griffin, P. T. Brief screening for alcohol use disorders in HIV primary care. *HIV Clin* **23**, 8–13 (2011).

13.Clary, C. R., Guidot, D. M., Bratina, M. A. & Otis, J. S. Chronic alcohol ingestion exacerbates skeletal muscle myopathy in HIV-1 transgenic rats. *AIDS Res Ther* **8**, 30 (2011).

## **V4 Human Immunodeficiency Virus and Bipolar disorder**

1. Yang, C.-Y., Su, T.-P., Wong, W.-W., Guo, W.-Y. & Su, Y.-L. Association of AIDS and bipolar mania with rapid progression to dementia and death. *J Chin Med Assoc* **68**, 92–95 (2005).
2. Ribeiro, C. M. F., Gurgel, W. S., Luna, J. R. G., Matos, K. J. N. & Souza, F. G. M. Is bipolar disorder a risk factor for HIV infection? *J Affect Disord* **146**, 66–70 (2013).
3. Posada, C. *et al.* Sustained attention deficits among HIV-positive individuals with comorbid bipolar disorder. *J Neuropsychiatry Clin Neurosci* **24**, 61–70 (2012).
4. Perretta, P. *et al.* The high prevalence of bipolar II and associated cyclothymic and hyperthymic temperaments in HIV-patients. *J Affect Disord* **50**, 215–224 (1998).
5. Murphy, K. *et al.* Treatment of HIV in outpatients with schizophrenia, schizoaffective disorder and bipolar disease at two county clinics. *Community Ment Health J* **47**, 668–671 (2011).
6. Moore, D. J. *et al.* HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence. *AIDS Behav* **16**, 2257–2266 (2012).
7. Meade, C. S., Bevilacqua, L. A. & Key, M. D. Bipolar disorder is associated with HIV transmission risk behavior among patients in treatment for HIV. *AIDS Behav* **16**, 2267–2271 (2012).
8. Lundberg, P. *et al.* HIV prevalence in persons with severe mental illness in Uganda: a cross-sectional hospital-based study. *Int J Ment Health Syst* **7**, 20 (2013).
9. De Sousa Gurgel, W. *et al.* Prevalence of bipolar disorder in a HIV-infected outpatient population. *AIDS Care* (2013). doi:10.1080/09540121.2013.779625

## **V4 Human Immunodeficiency Virus and Breast cancer**

1. Spano, J.-P. *et al.* Breast cancer among HIV infected individuals from the ONCOVIH study, in France: therapeutic implications. *Eur. J. Cancer* **48**, 3335–3341 (2012).
2. Sahali, S., Bichet, J.-C., Delfraissy, J.-F. & Ghosn, J. Breast enlargement in an HIV-infected man on combined antiretroviral therapy: what if it was carcinoma? *Int J STD AIDS* **21**, 373–374 (2010).
3. Ruiz, M. & Davis, H. Breast Cancer in HIV-Infected Patients: A Retrospective Single-Institution Study. *J Int Assoc Physicians AIDS Care (Chic)* **10**, 30–34 (2011).
4. Rastogi, M., Revannasiddaiah, S., Seam, R. K., Gupta, M. K. & Gupta, M. Extranodal lymphoma masquerading as carcinoma of the breast in an HIV-positive male patient. *BMJ Case Rep* **2012**, (2012).
5. Pantanowitz, L. *et al.* Spectrum of breast disease encountered in HIV-positive patients at a cluster teaching hospital. *Breast* **20**, 303–308 (2011).
6. Oluwole, S. F., Ali, A. O., Shafae, Z. & DePaz, H. A. Breast cancer in women with HIV/AIDS: report of five cases with a review of the literature. *J Surg Oncol* **89**, 23–27 (2005).
7. Momplaisir, F., Mounzer, K. & Long, J. A. Preventive cancer screening practices in HIV-positive patients. *AIDS Care* (2013).

doi:10.1080/09540121.2013.802276

8.Latif, N., Rana, F. & Guthrie, T. Breast cancer and HIV in the era of highly active antiretroviral therapy: two case reports and review of the literature. *Breast J* **17**, 87–92 (2011).

9.Jabłonowska, E., Kołacinska, A., Kuydowicz, J., Przybyłowska, K. & Jabłonowski, Z. Interleukin-6 and the IL-6 (-174) C/G polymorphism in breast pathologies and in HIV-infected patients. *Arch Med Sci* **6**, 860–865 (2010).

10.Hessol, N. A. *et al.* HIV tropism and decreased risk of breast cancer. *PLoS ONE* **5**, e14349 (2010).

11.Coghill, A. E. *et al.* Contribution of HIV infection to mortality among cancer patients in Uganda. *AIDS* (2013). doi:10.1097/01.aids.0000433236.55937.cb

12.Calabresi, A., Castelnovo, F., Ferraresi, A. & Quiros-Roldan, E. Male breast cancer in an HIV-infected patient: a case report. *Infez Med* **20**, 284–287 (2012).

13.Andrade, A. C. V. de *et al.* Breast cancer in a cohort of human immunodeficiency virus (HIV)-infected women from Rio de Janeiro, Brazil: a cases series report and an incidence rate estimate. *Braz J Infect Dis* **15**, 387–393 (2011).

## **V4 Human Immunodeficiency Virus and Chronic lymphocytic leukemia**

1.Ravandi, F., Verma, A., Ridgeway, J. & Pursell, K. Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications. *Leuk. Res.* **27**, 853–857 (2003).

2.Pulik, M., Genet, P., Jary, L., Lionnet, F. & Jondeau, K. Acute myeloid leukemias, multiple myelomas, and chronic leukemias in the setting of HIV infection. *AIDS Patient Care STDS* **12**, 913–919 (1998).

3.Mantina, H., Wiggill, T. M., Carmona, S., Perner, Y. & Stevens, W. S. Characterization of Lymphomas in a high prevalence HIV setting. *J. Acquir. Immune Defic. Syndr.* **53**, 656–660 (2010).

4.Lim, F. & Abdalla, S. H. Interactions between HIV infection and lymphoplasmacytoid lymphoma. *Leuk. Lymphoma* **47**, 163–166 (2006).

5.Cole, J., Pantanowitz, L. & Aboulafia, D. Human immunodeficiency virus and chronic lymphocytic leukemia. *Leuk. Lymphoma* **50**, 1885–1888 (2009).

## **V4 Human Immunodeficiency Virus and Coronary heart disease**

1.Zanni, M. V. *et al.* Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. *AIDS* **27**, 1263–1272 (2013).

2.Worm, S. W. *et al.* Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). *Circulation* **119**, 805–811 (2009).



3. Triant, V. A. HIV infection and coronary heart disease: an intersection of epidemics. *J. Infect. Dis.* **205 Suppl 3**, S355–361 (2012).
4. Syed, F. F. & Sani, M. U. Recent advances in HIV-associated cardiovascular diseases in Africa. *Heart* **99**, 1146–1153 (2013).
5. Savès, M. *et al.* Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. *Clin. Infect. Dis.* **37**, 292–298 (2003).
6. Rotger, M. *et al.* Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. *Clinical Infectious Diseases* **57**, 112–121 (2013).
7. Pullinger, C. R. *et al.* Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults. *Metab Syndr Relat Disord* **8**, 279–286 (2010).
8. Oh, J. Y., Greene, K., He, H., Schafer, S. & Hedberg, K. Population-based study of risk factors for coronary heart disease among HIV-infected persons. *Open AIDS J* **6**, 177–180 (2012).
9. Lai, H. *et al.* Vitamin D deficiency is associated with the development of subclinical coronary artery disease in African Americans with HIV infection: a preliminary study. *J. Invest. Med.* **60**, 801–807 (2012).
10. Hwang, J. J., Wei, J., Abbara, S., Grinspoon, S. K. & Lo, J. Receptor activator of nuclear factor- $\kappa$ B ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. *J. Acquir. Immune Defic. Syndr.* **61**, 359–363 (2012).
11. Funderburg, N. T. *et al.* Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. *Blood* **120**, 4599–4608 (2012).
12. Falcão, M. da C. B. de A. *et al.* Association of biomarkers with atherosclerosis and risk for coronary artery disease in patients with HIV. *Arq. Bras. Cardiol.* **99**, 971–978 (2012).
13. Esser, S. *et al.* Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. *Clin Res Cardiol* **102**, 203–213 (2013).
14. Campbell, L. J. *et al.* Renal impairment is associated with coronary heart disease in HIV-positive men. *HIV Clin Trials* **13**, 343–349 (2012).
15. Butt, A. A. *et al.* Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. *Arch. Intern. Med.* **171**, 737–743 (2011).
16. Boccara, F. *et al.* HIV and coronary heart disease: time for a better understanding. *J. Am. Coll. Cardiol.* **61**, 511–523 (2013).
17. Barros, Z. M. *et al.* Comparison between the Framingham and prospective cardiovascular of Münster scores for risk assessment of coronary heart disease in human immunodeficiency virus-positive patients in Pernambuco, Brazil. *Metab Syndr Relat Disord* **8**, 489–497 (2010).
18. Barakat, M. G. & Arora, R. R. Coronary Artery Disease in the Human Immunodeficiency Virus Seropositive Population. *Am J Ther* (2013).

## **V4 Human Immunodeficiency Virus and Crohn's disease**

1. Yoshida, E. M. & Whittaker, J. S. Crohn's disease, HIV, and AIDS. *Am. J. Gastroenterol.* **90**, 168 (1995).
2. Pospai, D. *et al.* Crohn's disease stable remission after human immunodeficiency virus infection. *Dig. Dis. Sci.* **43**, 412–419 (1998).
3. Moreno Sánchez, D., Solís Herruzo, J. A., Medina Asensio, J., Vargas Castrillón, J. & Colina Ruiz-Delgado, F. [Subclinical Crohn disease in acquired immunodeficiency syndrome]. *Rev Esp Enferm Dig* **84**, 395–398 (1993).
4. Lautenbach, E. & Lichtenstein, G. R. Human immunodeficiency virus infection and Crohn's disease: the role of the CD4 cell in inflammatory bowel disease. *J. Clin. Gastroenterol.* **25**, 456–459 (1997).
5. Kamat, A., Ancuta, P., Blumberg, R. S. & Gabuzda, D. Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation. *PLoS ONE* **5**, e15533 (2010).
6. James, S. P. Remission of Crohn's disease after human immunodeficiency virus infection. *Gastroenterology* **95**, 1667–1669 (1988).
7. Greenwald, B. & James, S. P. Long-term HIV infection with Crohn's disease. *Am. J. Gastroenterol.* **90**, 167–168 (1995).
8. Christ, A. D., Sieber, C. C., Cathomas, G. & Gyr, K. Concomitant active Crohn's disease and the acquired immunodeficiency syndrome. *Scand. J. Gastroenterol.* **31**, 733–735 (1996).
9. Bongiovanni, M., Ranieri, R., Ferrero, S., Casanova, F. & Monforte, A. d'Arminio. Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin. *AIDS* **20**, 1989–1990 (2006).
10. Bernstein, B. B., Gelb, A. & Tabanda-Lichauco, R. Crohn's ileitis in a patient with longstanding HIV infection. *Am. J. Gastroenterol.* **89**, 937–939 (1994).
11. Avilés-Izquierdo, J. A., Suárez-Fernández, R., Lázaro-Ochaita, P. & Longo-Imedio, I. Metastatic Crohn's disease mimicking genital pyoderma gangrenosum in an HIV patient. *Acta Derm. Venereol.* **85**, 60–62 (2005).
12. Apps, R. *et al.* Influence of HLA-C expression level on HIV control. *Science* **340**, 87–91 (2013).

## **V4 Human Immunodeficiency Virus and Inflammatory bowel disease**

1. Yoshida, E. M. & Whittaker, J. S. Crohn's disease, HIV, and AIDS. *Am. J. Gastroenterol.* **90**, 168 (1995).
2. Yoshida, E. M. *et al.* Human immunodeficiency virus infection, the acquired immunodeficiency syndrome, and inflammatory bowel disease. *J. Clin. Gastroenterol.* **23**, 24–28 (1996).
3. Viazis, N. *et al.* Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. *Inflamm. Bowel Dis.* **16**, 507–511 (2010).

4. Silver, S., Wahl, S. M., Orkin, B. A. & Orenstein, J. M. Changes in circulating levels of HIV, CD4, and tissue expression of HIV in a patient with recent-onset ulcerative colitis treated by surgery. Case report. *J. Hum. Virol.* **2**, 52–57 (1999).
5. Sharpstone, D. R., Duggal, A. & Gazzard, B. G. Inflammatory bowel disease in individuals seropositive for the human immunodeficiency virus. *Eur J Gastroenterol Hepatol* **8**, 575–578 (1996).
6. Olsson, J. *et al.* Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines. *J. Infect. Dis.* **182**, 1625–1635 (2000).
7. McGowan, I. M., Fairhurst, R. M., Shanahan, F. & Anton, P. A. Mucosal substance P receptor expression in HIV infection and inflammatory bowel disease. *Neuroimmunomodulation* **4**, 70–76 (1997).
8. Louis, E. *et al.* Extensive ulcerative colitis and extraintestinal manifestations in a patient with HIV infection and significant CD4 T-cell lymphopenia. *Gastroenterol. Clin. Biol.* **21**, 884–887 (1997).
9. Lautenbach, E. & Lichtenstein, G. R. Human immunodeficiency virus infection and Crohn's disease: the role of the CD4 cell in inflammatory bowel disease. *J. Clin. Gastroenterol.* **25**, 456–459 (1997).
10. Kotler, D. P., Reka, S. & Clayton, F. Intestinal mucosal inflammation associated with human immunodeficiency virus infection. *Dig. Dis. Sci.* **38**, 1119–1127 (1993).
11. Kawaguchi, T., Sako, M., Yoshimura, N., Takazoe, M. & Ryu, T. [A case of HIV infection associated with ulcerative colitis]. *Nihon Shokakibyo Gakkai Zasshi* **106**, 536–541 (2009).
12. Kamat, A., Ancuta, P., Blumberg, R. S. & Gabuzda, D. Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation. *PLoS ONE* **5**, e15533 (2010).
13. Hing, M. C., Goldschmidt, C., Mathijs, J. M., Cunningham, A. L. & Cooper, D. A. Chronic colitis associated with human immunodeficiency virus infection. *Med. J. Aust.* **156**, 683–687 (1992).
14. Greenwald, B. & James, S. P. Long-term HIV infection with Crohn's disease. *Am. J. Gastroenterol.* **90**, 167–168 (1995).
15. Fu, C. S., Contreas, C. N. & LaRiviere, M. J. Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus. *AIDS Patient Care STDS* **12**, 903–906 (1998).
16. Christ, A. D., Sieber, C. C., Cathomas, G. & Gyr, K. Concomitant active Crohn's disease and the acquired immunodeficiency syndrome. *Scand. J. Gastroenterol.* **31**, 733–735 (1996).
17. Bernstein, B. B., Gelb, A. & Tabanda-Lichauco, R. Crohn's ileitis in a patient with longstanding HIV infection. *Am. J. Gastroenterol.* **89**, 937–939 (1994).
18. Ballinger, A., Kelly, P., Hallyburton, E., Besser, R. & Farthing, M. Plasma leptin in chronic inflammatory bowel disease and HIV: implications for the viruses of anorexia and weight loss. *Clin. Sci.* **94**, 479–483 (1998).

## V4 Human Immunodeficiency Virus and Multiple sclerosis

- 1.Rezai-Zadeh, K., Gate, D. & Town, T. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? *J Neuroimmune Pharmacol* **4**, 462–475 (2009).
- 2.Nkoghe, D., Moutschen, M. & Demonty, J. [Demyelinating cerebral lesions in an immunocompetent HIV-1 patient]. *Med Mal Infect* **38**, 500–503 (2008).
- 3.Nexø, B. A., Pedersen, L., Sørensen, H. T. & Koch-Henriksen, N. Treatment of HIV and Risk of Multiple Sclerosis: *Epidemiology* **24**, 331–332 (2013).
- 4.Mechelli, R. *et al.* A ‘Candidate-Interactome’ Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis. *PLoS One* **8**, (2013).
- 5.Limou, S. *et al.* Identification of IL7RA risk alleles for rapid progression during HIV-1 infection: a comprehensive study in the GRIV cohort. *Curr. HIV Res.* **10**, 143–150 (2012).
- 6.Lee, J., Phong, B., Egloff, A. M. & Kane, L. P. TIM polymorphisms--genetics and function. *Genes Immun.* **12**, 595–604 (2011).
- 7.Lackner, P. *et al.* Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study. *J Neuroinflammation* **7**, 79 (2010).
- 8.He, F. & Balling, R. The role of regulatory T cells in neurodegenerative diseases. *Wiley Interdiscip Rev Syst Biol Med* **5**, 153–180 (2013).
- 9.Gray, F. *et al.* Fulminating multiple sclerosis-like leukoencephalopathy revealing human immunodeficiency virus infection. *Neurology* **41**, 105–109 (1991).
- 10.González-Duarte, A., Ramirez, C., Pinales, R. & Sierra-Madero, J. Multiple sclerosis typical clinical and MRI findings in a patient with HIV infection. *J. Neurovirol.* **17**, 504–508 (2011).
- 11.Facchini, S. A., Harding, S. A. & Waldron, R. L. Human immunodeficiency virus-1 infection and multiple sclerosis-like illness in a child. *Pediatr. Neurol.* **26**, 231–235 (2002).
- 12.De Chiara, G. *et al.* Infectious agents and neurodegeneration. *Mol. Neurobiol.* **46**, 614–638 (2012).
- 13.D’Aversa, T. G., Weidenheim, K. M. & Berman, J. W. CD40-CD40L interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus encephalitis and multiple sclerosis. *Am. J. Pathol.* **160**, 559–567 (2002).
- 14.Borjabad, A. & Volsky, D. J. Common Transcriptional Signatures in Brain Tissue from Patients with HIV-Associated Neurocognitive Disorders, Alzheimer’s Disease, and Multiple Sclerosis. *J Neuroimmune Pharmacol* **7**, 914–926 (2012).
- 15.Ashkenazi, A., Faingold, O., Kaushansky, N., Ben-Nun, A. & Shai, Y. A highly conserved sequence associated with the HIV gp41 loop region is an immunomodulator of antigen-specific T cells in mice. *Blood* **121**, 2244–2252 (2013).

## V4 Human Immunodeficiency Virus and Schizophrenia

1. Walkup, J. T. *et al.* Prevalence of diagnosed HIV disease among medicaid beneficiaries with schizophrenia in U.S. metropolitan areas. *J. Nerv. Ment. Dis.* **198**, 682–686 (2010).
2. Vlassova, N., Angelino, A. F. & Treisman, G. J. Update on mental health issues in patients with HIV infection. *Curr Infect Dis Rep* **11**, 163–169 (2009).
3. Vahia, V. N., Bhojraj, T. & Creado, D. A. Neurocognitive deficits in HIV-positive patients-two case reports: Revising current AANTF guidelines in view of recent revelation of new neurocognitive symptoms. *Indian J Psychiatry* **48**, 193–195 (2006).
4. Minagar, A. *et al.* HIV-associated dementia, Alzheimer's disease, multiple sclerosis, and schizophrenia: gene expression review. *Journal of the Neurological Sciences* **224**, 3–17 (2004).
5. Koen, L., Vuuren, S. V., Niehaus, D. J. H. & Emsley, R. A. HIV/AIDS risk behaviour in South African schizophrenia patients. *West Afr J Med* **26**, 2–6 (2007).
6. Himelhoch, S. *et al.* Understanding associations between serious mental illness and HIV among patients in the VA Health System. *Psychiatr Serv* **58**, 1165–1172 (2007).
7. Hashimoto, T. *et al.* Acute schizophrenic symptoms as the initial manifestation of HIV infection that respond to highly active antiretroviral therapy. *Clin. Infect. Dis.* **42**, 1653–1655 (2006).
8. Gibson, R. C. *et al.* HIV seroprevalence among hospital inpatients with neuropsychiatric and other central nervous system disorders. *West Indian Med J* **59**, 434–438 (2010).
9. De Ronchi, D. *et al.* Psychopathology of first-episode psychosis in HIV-positive persons in comparison to first-episode schizophrenia: a neglected issue. *AIDS Care* **18**, 872–878 (2006).
10. Cournos, F., McKinnon, K. & Sullivan, G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. *J Clin Psychiatry* **66 Suppl 6**, 27–33 (2005).
11. Blank, M. B., Mandell, D. S., Aiken, L. & Hadley, T. R. Co-occurrence of HIV and serious mental illness among Medicaid recipients. *Psychiatr Serv* **53**, 868–873 (2002).
12. Baillargeon, J. G. *et al.* Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting. *AIDS Care* **20**, 124–129 (2008).

## **V4 Human Immunodeficiency Virus and Type 2 diabetes**

1. Tebas, P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: virology, prevention, and treatment options. *J. Acquir. Immune Defic. Syndr.* **49 Suppl 2**, S86–92 (2008).
2. Szep, Z. *et al.* Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. *AIDS* **25**, 525–529 (2011).
3. Shikuma, C. M., Day, L. J. & Gerschenson, M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. *Curr Drug*

*Targets Infect Disord* **5**, 255–262 (2005).

4.Samaras, K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. *Curr HIV/AIDS Rep* **9**, 206–217 (2012).

5.Samaras, K. Prevalence and viruses of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. *J. Acquir. Immune Defic. Syndr.* **50**, 499–505 (2009).

6.Salehian, B., Bilas, J., Bazargan, M. & Abbasian, M. Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors. *J Natl Med Assoc* **97**, 1088–1092 (2005).

7.Perciaccante, A., Zanette, G. & Donadon, V. Type 2 diabetes mellitus and increased prevalence of hepatocarcinoma in HIV-infected population. *J. Acquir. Immune Defic. Syndr.* **49**, 573 (2008).

8.Narayan, K. M. V., Ali, M. K., del Rio, C., Koplan, J. P. & Curran, J. Global Noncommunicable Diseases — Lessons from the HIV–AIDS Experience. *New England Journal of Medicine* **365**, 876–878 (2011).

9.Miranda, M. *et al.* Human subcutaneous adipose tissue LPIN1 expression in obesity, type 2 diabetes mellitus, and human immunodeficiency virus--associated lipodystrophy syndrome. *Metab. Clin. Exp.* **56**, 1518–1526 (2007).

10.Magee, M. J. & Narayan, K. M. V. Global confluence of infectious and non-communicable diseases - The case of type 2 diabetes. *Prev Med* (2013). doi:10.1016/j.ypmed.2013.05.027

11.Ledergerber, B. *et al.* Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. *Clin. Infect. Dis.* **45**, 111–119 (2007).

12.Han, J. H. *et al.* HIV infection and glycemic response to newly initiated diabetic medical therapy. *AIDS* **26**, 2087–2095 (2012).

13.Galli, L. *et al.* Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. *Eur. J. Epidemiol.* **27**, 657–665 (2012).

14.Deloumeaux, J. *et al.* Adiponectin and leptin in Afro-Caribbean men and women with HIV infection: association with insulin resistance and type 2 diabetes. *Diabetes Metab.* **37**, 98–104 (2011).

15.Carper, M. J. *et al.* HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. *Am. J. Physiol. Endocrinol. Metab.* **294**, E558–567 (2008).

16.Butt, A. A. *et al.* HIV infection and the risk of diabetes mellitus. *AIDS* **23**, 1227–1234 (2009).

## **V4 Influenza A Virus and Alcohol dependence**

1.Mukhopadhyay, S., Philip, A. T. & Stoppacher, R. Pathologic findings in novel influenza A (H1N1) virus ('Swine Flu') infection: contrasting clinical manifestations and lung pathology in two fatal cases. *Am. J. Clin. Pathol.* **133**, 380–387 (2010).

2.Meyerholz, D. K. *et al.* Chronic alcohol consumption increases the severity of murine influenza virus infections. *J. Immunol.* **181**, 641–648 (2008).

3. Glezen, W. P., Falcao, O., Cate, T. R. & Mintz, A. A. Nosocomial influenza in a general hospital for indigent patients. *Can J Infect Control* **6**, 65–67 (1991).

#### **V4 Influenza A Virus and Bipolar disorder**

1. Okusaga, O. *et al.* Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts. *J Affect Disord* **130**, 220–225 (2011).

#### **V4 Influenza A Virus and Breast cancer**

1. Meerveld-Eggink, A. *et al.* Response to influenza virus vaccination during chemotherapy in patients with breast cancer. *Ann. Oncol.* **22**, 2031–2035 (2011).

2. Loulergue, P. *et al.* Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. *Br. J. Cancer* **104**, 1670–1674 (2011).

3. Felaco, P. *et al.* IL-32: a newly-discovered proinflammatory cytokine. *J. Biol. Regul. Homeost. Agents* **23**, 141–147 (2009).

#### **V4 Influenza A Virus and Chronic lymphocytic leukemia**

1. Lai, S., Merritt, B. Y., Chen, L., Zhou, X. & Green, L. K. Hemophagocytic lymphohistiocytosis associated with influenza A (H1N1) infection in a patient with chronic lymphocytic leukemia: an autopsy case report and review of the literature. *Ann Diagn Pathol* **16**, 477–484 (2012).

2. El-Badrawy, A., Zeidan, A. & Ebrahim, M. A. 64 multidetector CT findings of influenza A (H1N1) virus in patients with hematologic malignancies. *Acta Radiol* **53**, 662–667 (2012).

#### **V4 Influenza A Virus and Coronary heart disease**

1. Song, B. G. *et al.* Clinical features in adult patients with in-hospital cardiovascular events with confirmed 2009 Influenza A (H1N1) virus infection: comparison with those without in-hospital cardiovascular events. *J Chin Med Assoc* **75**, 435–441 (2012).

2. Pleskov, V. M., Bannikov, A. I., Gurevich, V. S. & Pleskova, I. V. [Influenza viruses and atherosclerosis: the role of atherosclerotic plaques in prolonging the persistent form of influenza infection]. *Vestn. Akad. Med. Nauk SSSR* 10–13 (2003).

3. Madjid, M., Alfred, A., Sahai, A., Conyers, J. L. & Casscells, S. W. Factors contributing to suboptimal vaccination against influenza: results of a nationwide telephone survey of persons with cardiovascular disease. *Tex Heart Inst J* **36**, 546–552 (2009).

4. Lippi, G., Franchini, M. & Favaloro, E. J. Influenza and cardiovascular disease:

does swine-origin, 2009 H1N1 flu virus represent a risk factor, an acute trigger, or both? *Semin. Thromb. Hemost.* **36**, 49–58 (2010).

5. Lewicki, L. *et al.* Acute coronary artery thrombosis during the postpartum period complicated by cardiogenic shock and AH1N1 infection. *Kardiol Pol* **70**, 1079 (2012).

6. Gurevich, V. S. *et al.* [Influenza virus infection in progressing atherosclerosis]. *Kardiologia* **42**, 21–24 (2002).

7. Garnacho-Montero, J. *et al.* Epidemiology, clinical features, and prognosis of elderly adults with severe forms of influenza A (H1N1). *J Am Geriatr Soc* **61**, 350–356 (2013).

8. Erden, I., Erden, E. C., Ozhan, H. & Basar, C. Acute myocarditis mimicking acute myocardial infarction associated with pandemic 2009 (H1N1) influenza A virus. *Cardiol J* **18**, 552–555 (2011).

9. Bondarenko, S. S. & Tumanov, F. A. [The effect of influenza and para-influenza on the course of ischemic heart disease]. *Ter. Arkh.* **64**, 81–83 (1992).

10. Bondarenko, S. S. & Tumanov, F. A. [The incidence of exacerbations in chronic diseases in patients hospitalized with influenza and para-influenza]. *Ter. Arkh.* **62**, 39–42 (1990).

11. Bogomolov, B. P. & Mol'kova, T. N. [State of the cardiovascular system in influenza in patients with ischemic heart disease]. *Ter. Arkh.* **52**, 31–34 (1980).

12. Auer, J. *et al.* Influenza A and B IgG seropositivity and coronary atherosclerosis assessed by angiography. *Heart Dis* **4**, 349–354 (2002).

13. Auer, J., Berent, R., Weber, T. & Eber, B. Influenza virus infection, infectious burden, and atherosclerosis. *Stroke* **33**, 1454–1455 (2002).

14. Arbit, B., Gaultier, C. R. & Schwarz, E. R. H1N1 virus infection associated with acute myocardial infarction in a young patient without coronary artery disease--first reported case. *Acta Cardiol* **66**, 807–810 (2011).

15. Agnino, A., Schena, S., Ferlan, G. & De Luca Tupputi Schinosa, L. Left ventricular pseudoaneurysm after acute influenza A myocardiopericarditis. *J Cardiovasc Surg (Torino)* **43**, 203–205 (2002).

## **V4 Influenza A Virus and Crohn's disease**

1. Pillot, C., Chevaux, J.-B., Petitpain, N. & Peyrin-Biroulet, L. Acute hepatic cytolysis following H1N1 vaccination in a patient with Crohn's disease on infliximab. *Inflamm. Bowel Dis.* **17**, 679 (2011).

2. Lisotti, A., Roda, G., Brillanti, S. & Roda, E. Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations. *Dig Liver Dis* **42**, 909–910 (2010).

## **V4 Influenza A Virus and Inflammatory bowel disease**

1. Romanowska, M., Banaszkiwicz, A., Nowak, I., Radzikowski, A. & Brydak, L. B. Immunization against influenza during the 2005/2006 epidemic season and the



humoral response in children with diagnosed inflammatory bowel disease (IBD). *Med. Sci. Monit.* **16**, CR433–439 (2010).

2.Rahier, J.-F., Yazdanpanah, Y., Viget, N., Travis, S. & Colombel, J.-F. Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. *Aliment. Pharmacol. Ther.* **31**, 5–10 (2010).

3.Rahier, J.-F. *et al.* Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series. *Aliment. Pharmacol. Ther.* **33**, 499–500 (2011).

4.Rahier, J.-F. *et al.* H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. *Gut* **60**, 456–462 (2011).

5.Pillot, C., Chevaux, J.-B., Petitpain, N. & Peyrin-Biroulet, L. Acute hepatic cytolysis following H1N1 vaccination in a patient with Crohn's disease on infliximab. *Inflamm. Bowel Dis.* **17**, 679 (2011).

6.Narula, N., Dhillon, A. S., Chauhan, U. & Marshall, J. K. An audit of influenza vaccination status in adults with inflammatory bowel disease. *Can. J. Gastroenterol.* **26**, 593–596 (2012).

7.Molnár, T. *et al.* Appropriate response to influenza A (H1N1) virus vaccination in patients with inflammatory bowel disease on maintenance immunomodulator and/or biological therapy. *Am. J. Gastroenterol.* **106**, 370–372 (2011).

8.Mamula, P. *et al.* Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. *Clin. Gastroenterol. Hepatol.* **5**, 851–856 (2007).

9.Lu, Y. *et al.* Immune response to influenza vaccine in children with inflammatory bowel disease. *Am. J. Gastroenterol.* **104**, 444–453 (2009).

10.Lisotti, A., Roda, G., Brilianti, S. & Roda, E. Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations. *Dig Liver Dis* **42**, 909–910 (2010).

11.Kyriakos, N., Papamichael, K., Archavlis, E., Agalos, G. & Mantzaris, G. J. Long term safety and efficacy of H1N1 vaccine in a single-center cohort of IBD patients treated with immunomodulators and/or anti-TNF $\alpha$  biologics. *J Crohns Colitis* **6**, 264–265 (2012).

12.Hernández-Guerra, M. *et al.* Immunogenicity and acceptance of influenza A (H1N1) vaccine in a cohort of chronic hepatitis C patients receiving pegylated-interferon treatment. *PLoS ONE* **7**, e48610 (2012).

13.Hanna, M. & Poullis, A. Sub-optimal H1N1 vaccine uptake by immunocompromised inflammatory bowel disease patients. *Clin Med* **11**, 301 (2011).

14.Gelinck, L. B. S. *et al.* The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. *Ann. Rheum. Dis.* **67**, 713–716 (2008).

15.Frasca, D. *et al.* AID in aging and autoimmune diseases. *Autoimmunity* **46**, 168–175 (2013).

16.Fields, S. W., Baiocco, P. J. & Korelitz, B. I. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives? *Inflamm. Bowel Dis.* **15**, 649–651; author reply 651–652 (2009).

17.Farkas, K. *et al.* [The efficiency of influenza vaccines in patients with

inflammatory bowel disease on immunosuppressive therapy]. *Orv Hetil* **153**, 1870–1874 (2012).

18.deBruyn, J. C. C. *et al.* Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. *Inflamm. Bowel Dis.* **18**, 25–33 (2012).

19.Cullen, G., Bader, C., Korzenik, J. R. & Sands, B. E. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. *Gut* **61**, 385–391 (2012).

20.Bardage, C. *et al.* Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. *BMJ* **343**, d5956 (2011).

## **V4 Influenza A Virus and Multiple sclerosis**

1.Oztürk, S. Swine flu vaccine adjuvants and multiple sclerosis - Is there potential for harmful effect? *Med. Hypotheses* **75**, 50–52 (2010).

2.Oikonen, M. *et al.* Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence. *Mult. Scler.* **17**, 672–680 (2011).

3.Moriabadi, N. F. *et al.* Influenza vaccination in MS: absence of T-cell response against white matter proteins. *Neurology* **56**, 938–943 (2001).

4.Mokhtarian, F. *et al.* Influenza virus vaccination of patients with multiple sclerosis. *Mult. Scler.* **3**, 243–247 (1997).

5.McNicholas, N. & Chataway, J. Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. *J. Neurol.* **258**, 1545–1547 (2011).

6.Isai, A., Durand, J., Le Meur, S., Hidalgo-Simon, A. & Kurz, X. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. *Vaccine* **30**, 7123–7129 (2012).

7.De la Monte, S. M. *et al.* Relapsing central and peripheral demyelinating diseases. Unusual pathologic features. *Arch. Neurol.* **43**, 626–629 (1986).

8.Bardage, C. *et al.* Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. *BMJ* **343**, d5956 (2011).

9.Auriel, E., Gadoth, A., Regev, K. & Karni, A. Seasonal and H1N1v influenza vaccines in MS: safety and compliance. *J. Neurol. Sci.* **314**, 102–103 (2012).

## **V4 Influenza A Virus and Schizophrenia**

1.Winter, C. *et al.* Dopamine and serotonin levels following prenatal viral infection in mouse--implications for psychiatric disorders such as schizophrenia and autism. *Eur Neuropsychopharmacol* **18**, 712–716 (2008).

2.Venables, P. H., Liu, J., Raine, A. & Mednick, S. A. Prenatal influenza exposure and delivery complications: implications for the development of schizophrenia. *Fam Community Health* **30**, 151–159 (2007).

- 3.Short, S. J. *et al.* Maternal influenza infection during pregnancy impacts postnatal brain development in the rhesus monkey. *Biol. Psychiatry* **67**, 965–973 (2010).
- 4.Shi, L. *et al.* Activation of the maternal immune system alters cerebellar development in the offspring. *Brain Behav. Immun.* **23**, 116–123 (2009).
- 5.Moreno, J. L. *et al.* Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT<sub>2A</sub> and mGlu<sub>2</sub> receptors in the adult offspring. *J. Neurosci.* **31**, 1863–1872 (2011).
- 6.Manjunatha, N. The current swine flu pandemic may provide some opportunity for future research of schizophrenia. *Indian J. Med. Res.* **132**, 108–109 (2010).
- 7.Landreau, F. *et al.* Effects of two commonly found strains of influenza A virus on developing dopaminergic neurons, in relation to the pathophysiology of schizophrenia. *PLoS ONE* **7**, e51068 (2012).
- 8.Fatemi, S. H., Reutiman, T. J., Folsom, T. D. & Sidwell, R. W. The role of cerebellar genes in pathology of autism and schizophrenia. *Cerebellum* **7**, 279–294 (2008).
- 9.Fatemi, S. H. *et al.* Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. *Schizophr. Res.* **99**, 56–70 (2008).
- 10.Fatemi, S. H. *et al.* The viral theory of schizophrenia revisited: abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring. *Neuropharmacology* **62**, 1290–1298 (2012).
- 11.Fatemi, S. H. *et al.* Prenatal viral infection of mice at E16 causes changes in gene expression in hippocampi of the offspring. *Eur Neuropsychopharmacol* **19**, 648–653 (2009).
- 12.Fatemi, S. H. *et al.* Abnormal expression of myelination genes and alterations in white matter fractional anisotropy following prenatal viral influenza infection at E16 in mice. *Schizophr. Res.* **112**, 46–53 (2009).
- 13.Fatemi, S. H., Pearce, D. A., Brooks, A. I. & Sidwell, R. W. Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. *Synapse* **57**, 91–99 (2005).
- 14.Ellman, L. M., Yolken, R. H., Buka, S. L., Torrey, E. F. & Cannon, T. D. Cognitive functioning prior to the onset of psychosis: the role of fetal exposure to serologically determined influenza infection. *Biol. Psychiatry* **65**, 1040–1047 (2009).
- 15.Crosby, D., Peterson, J. & Carroll, B. T. Atypical neuroleptic malignant syndrome in H1N1 pneumonia. *Ann Clin Psychiatry* **25**, 69–70 (2013).
- 16.Brown, A. S. *et al.* Serologic evidence of prenatal influenza in the etiology of schizophrenia. *Arch. Gen. Psychiatry* **61**, 774–780 (2004).

## **V4 Influenza A Virus and Ulcerative colitis**

- 1.Rahier, J.-F. *et al.* H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological

therapy. *Gut* **60**, 456–462 (2011).

2.Lu, Y. *et al.* Immune response to influenza vaccine in children with inflammatory bowel disease. *Am. J. Gastroenterol.* **104**, 444–453 (2009).

3.Kyriakos, N., Papamichael, K., Archavlis, E., Agalos, G. & Mantzaris, G. J. Long term safety and efficacy of H1N1 vaccine in a single-center cohort of IBD patients treated with immunomodulators and/or anti-TNF $\alpha$  biologics. *J Crohns Colitis* **6**, 264–265 (2012).

4.Fields, S. W., Baiocco, P. J. & Korelitz, B. I. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives? *Inflamm. Bowel Dis.* **15**, 649–651; author reply 651–652 (2009).

## **V4 Lymphocytic Choriomeningitis Virus and Chronic lymphocytic leukemia**

1.Mumprecht, S., Schürch, C., Schwaller, J., Solenthaler, M. & Ochsenbein, A. F. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. *Blood* **114**, 1528–1536 (2009).

2.Mumprecht, S., Schürch, C., Scherrer, S., Claus, C. & Ochsenbein, A. F. Chronic myelogenous leukemia maintains specific CD8(+) T cells through IL-7 signaling. *Eur. J. Immunol.* **40**, 2720–2730 (2010).

3.Mumprecht, S., Matter, M., Pavelic, V. & Ochsenbein, A. F. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. *Blood* **108**, 3406–3413 (2006).

4.Mumprecht, S. *et al.* Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. *Blood* **113**, 4681–4689 (2009).

5.Li, N. *et al.* Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. *Blood* **118**, 5965–5976 (2011).

6.Campbell Dwyer, E. J., Lai, H., MacDonald, R. C., Salvato, M. S. & Borden, K. L. The lymphocytic choriomeningitis virus RING protein Z associates with eukaryotic initiation factor 4E and selectively represses translation in a RING-dependent manner. *J. Virol.* **74**, 3293–3300 (2000).

7.Borden, K. L., CampbellDwyer, E. J. & Salvato, M. S. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING domain. *FEBS Lett.* **418**, 30–34 (1997).

## **V4 Lymphocytic Choriomeningitis Virus and Inflammatory bowel disease**

1.Olivares-Villagómez, D. *et al.* Thymus leukemia antigen controls intraepithelial lymphocyte function and inflammatory bowel disease. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 17931–17936 (2008).

2.Nancey, S. *et al.* Blockade of LTB(4) /BLT(1) pathway improves CD8(+) T-cell-mediated colitis. *Inflamm. Bowel Dis.* **17**, 279–288 (2011).

## **V4 Lymphocytic Choriomeningitis Virus and Multiple sclerosis**

1.McCoy, L., Tsunoda, I. & Fujinami, R. S. Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation. *Autoimmunity* **39**, 9–19 (2006).

2.Matullo, C. M., O'Regan, K. J., Curtis, M. & Rall, G. F. CNS recruitment of CD8+ T lymphocytes specific for a peripheral virus infection triggers neurovirogenesis during polymicrobial challenge. *PLoS Pathog.* **7**, e1002462 (2011).

## **V4 Lymphocytic Choriomeningitis Virus and Schizophrenia**

1.Vasil'eva, O. A., Kriukova, L. K. & Podoplekina, L. E. [Antibodies to measles, smallpox, influenza and arenaviruses in schizophrenic patients]. *Zh Nevropatol Psikhiatr Im S S Korsakova* **86**, 106–108 (1986).

2.Pearce, B. D., Valadi, N. M., Po, C. L. & Miller, A. H. Viral infection of developing GABAergic neurons in a model of hippocampal disinhibition. *Neuroreport* **11**, 2433–2438 (2000).

3.Pearce, B. D. Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms. *Mol. Psychiatry* **6**, 634–646 (2001).

4.Bonthius, D. J. & Perlman, S. Congenital viral infections of the brain: lessons learned from lymphocytic choriomeningitis virus in the neonatal rat. *PLoS Pathog.* **3**, e149 (2007).

## **V5 Herpesvirus 4, Human and Bipolar disorder**

1.Cooke, R. G., Warsh, J. J., Hasey, G. M., McLaughlin, B. J. & Jorna, T. Epstein-Barr virus antibodies and severity of depression. *Biol. Psychiatry* **29**, 621–623 (1991).

2.Cooke, R. G., Langlet, F. & McLaughlin, B. J. Age-specific prevalence of Epstein-Barr virus antibodies in adult patients with affective disorders. *J Clin Psychiatry* **49**, 361–363 (1988).

## **V5 Herpesvirus 4, Human and Bipolar disorder and schizophrenia**

1.Rosenfeld, M., Brenner-Lavie, H., Ari, S. G.-B., Kavushansky, A. & Ben-Shachar, D. Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. *Biol. Psychiatry* **69**, 980–988 (2011).

## **V5 Herpesvirus 4, Human and Breast cancer**

1. Murray, P. G. Epstein-Barr virus in breast cancer: artefact or aetiological agent? *J. Pathol.* **209**, 427–429 (2006).
2. Mazouni, C. *et al.* Epstein-Barr virus as a marker of biological aggressiveness in breast cancer. *Br. J. Cancer* **104**, 332–337 (2011).
3. Lorenzetti, M. A. *et al.* Characterization of Epstein Barr virus latency pattern in Argentine breast carcinoma. *PLoS ONE* **5**, e13603 (2010).
4. Liu, Y., Fan, S. & Lu, M. [Relationship between Epstein-Barr virus and breast tumors]. *Zhonghua Bing Li Xue Za Zhi* **37**, 269–271 (2008).
5. Khan, G., Philip, P. S., Al Ashari, M., Houcinat, Y. & Daoud, S. Localization of Epstein-Barr virus to infiltrating lymphocytes in breast carcinomas and not malignant cells. *Exp. Mol. Pathol.* **91**, 466–470 (2011).
6. Kalkan, A. *et al.* Investigation of Epstein-Barr virus DNA in formalin-fixed and paraffin- embedded breast cancer tissues. *Med Princ Pract* **14**, 268–271 (2005).
7. Joshi, D. & Buehring, G. C. Are viruses associated with human breast cancer? Scrutinizing the molecular evidence. *Breast Cancer Res. Treat.* **135**, 1–15 (2012).
8. Huo, Q., Zhang, N. & Yang, Q. Epstein-Barr virus infection and sporadic breast cancer risk: a meta-analysis. *PLoS ONE* **7**, e31656 (2012).
9. Hippocrate, A., Oussaief, L. & Joab, I. Possible role of EBV in breast cancer and other unusually EBV-associated cancers. *Cancer Lett.* **305**, 144–149 (2011).
10. He, J.-R. *et al.* Epstein-Barr virus and breast cancer: serological study in a high-incidence area of nasopharyngeal carcinoma. *Cancer Lett.* **309**, 128–136 (2011).
11. He, J.-R. *et al.* Joint effects of Epstein-Barr virus and polymorphisms in interleukin-10 and interferon- $\gamma$  on breast cancer risk. *J. Infect. Dis.* **205**, 64–71 (2012).
12. Glenn, W. K., Whitaker, N. J. & Lawson, J. S. High risk human papillomavirus and Epstein Barr virus in human breast milk. *BMC Res Notes* **5**, 477 (2012).
13. Glenn, W. K. *et al.* Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. *PLoS ONE* **7**, e48788 (2012).
14. Fagundes, C. P. *et al.* Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. *Brain Behav. Immun.* **26**, 394–400 (2012).
15. Cox, B. *et al.* Breast cancer, cytomegalovirus and Epstein-Barr virus: a nested case-control study. *Br. J. Cancer* **102**, 1665–1669 (2010).
16. Arbach, H. *et al.* Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). *J. Virol.* **80**, 845–853 (2006).
17. Amarante, M. K. & Watanabe, M. A. E. The possible involvement of virus in breast cancer. *J. Cancer Res. Clin. Oncol.* **135**, 329–337 (2009).

## V5 Herpesvirus 4, Human and Celiac disease

1. Plot, L. *et al.* Infections may have a protective role in the etioviruses of celiac disease. *Ann. N. Y. Acad. Sci.* **1173**, 670–674 (2009).
2. Ilyas, M. *et al.* Non-Hodgkin's lymphoma, coeliac disease, and Epstein-Barr virus: a study of 13 cases of enteropathy-associated T- and B-cell lymphoma. *J.*

*Pathol.* **177**, 115–122 (1995).

3.Harada, S. *et al.* Epstein-Barr virus specific antibodies in patients with coeliac disease. *Ir J Med Sci* **154**, 416–421 (1985).

## **V5 Herpesvirus 4, Human and Coronary heart disease**

1.Tyson, A. A., Jr, Hackshaw, B. T. & Kutcher, M. A. Acute Epstein-Barr virus myocarditis simulating myocardial infarction with cardiogenic shock. *South. Med. J.* **82**, 1184–1187 (1989).

2.Schlitt, A. *et al.* Herpesvirus DNA (Epstein-Barr virus, herpes simplex virus, cytomegalovirus) in circulating monocytes of patients with coronary artery disease. *Acta Cardiol* **60**, 605–610 (2005).

3.Rupprecht, H. J. *et al.* Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. *Circulation* **104**, 25–31 (2001).

4.Ogurtsov, P. P., Stepina, V. N., Rukosuev, V. S. & Nanaev, A. K. [Epstein-Barr virus infection and congestive cardiomyopathy (serologic and immunomorphologic aspects)]. *Biull Vsesoiuznogo Kardiolog Nauchn Tsentra AMN SSSR* **11**, 18–22 (1988).

5.Nakagawa, A. *et al.* Chronic active Epstein-Barr virus infection with giant coronary aneurysms. *Am. J. Clin. Pathol.* **105**, 733–736 (1996).

6.Murakami, K. *et al.* Large-vessel arteritis associated with chronic active Epstein-Barr virus infection. *Arthritis Rheum.* **41**, 369–373 (1998).

7.Muneuchi, J. *et al.* Cardiovascular complications associated with chronic active Epstein-Barr virus infection. *Pediatr Cardiol* **30**, 274–281 (2009).

8.Kupchinskiĭ, R. A., Matskin, L. I., Azarovskaia, T. N. & Stepina, V. N. [Correlation of the level of humoral antibodies to the Epstein-Barr virus and the clinical course of atherosclerosis]. *Vopr. Virusol.* **33**, 479–481 (1988).

9.Krylov, A. A. & Kupchinskiĭ, R. A. [The role of persistent Epstein-Barr herpesvirus infection in the etiology of arteriosclerosis and its complications]. *Kardiologiya* **31**, 74–77 (1991).

10.Krylov, A. A. & Kupchinskiĭ, R. A. [Atherosclerosis and chronic persistent virus infection]. *Vrach Delo* 43–46 (1990).

11.Kobayashi, I. *et al.* Chronic Epstein-Barr virus infections associated with coronary aneurysms. *Acta Paediatr Jpn* **31**, 509–512 (1989).

12.Kikuta, H. *et al.* Detection of Epstein-Barr virus DNA in cardiac and aortic tissues from chronic, active Epstein-Barr virus infection associated with Kawasaki disease-like coronary artery aneurysms. *J. Pediatr.* **123**, 90–92 (1993).

13.De Backer, J. *et al.* Parameters of inflammation and infection in a cluster based case-control study of coronary heart disease. *Atherosclerosis* **160**, 457–463 (2002).

14.Davutoğlu, V., Ercan, S. & Oylumlu, M. Microorganisms and valve tissue/demonstration of *Chlamydomphila pneumoniae*, *Mycoplasma pneumoniae*, Cytomegalovirus, and Epstein-Barr virus in atherosclerotic coronary arteries, nonrheumatic calcific aortic and rheumatic stenotic mitral valves by polymerase chain reaction. *Anadolu Kardiyol Derg* **11**, 564; author reply 564–565 (2011).

- 15.Culora, G. A. & Moore, I. E. Kawasaki disease, Epstein-Barr virus and coronary artery aneurysms. *J. Clin. Pathol.* **50**, 161–163 (1997).
- 16.Bayram, A., Erdoğan, M. B., Ekşi, F. & Yamak, B. Demonstration of Chlamydia pneumoniae, Mycoplasma pneumoniae, Cytomegalovirus, and Epstein-Barr virus in atherosclerotic coronary arteries, nonrheumatic calcific aortic and rheumatic stenotic mitral valves by polymerase chain reaction. *Anadolu Kardiyol Derg* **11**, 237–243 (2011).
- 17.Andrié, R., Braun, P., Heinrich, K.-W., Lüderitz, B. & Bauriedel, G. [Prevalence of intimal virus burden in acute coronary syndromes]. *Z Kardiol* **92**, 641–649 (2003).
- 18.Al-Ghamdi, A. Role of herpes simplex virus-1, cytomegalovirus and Epstein-Barr virus in atherosclerosis. *Pak J Pharm Sci* **25**, 89–97 (2012).

## **V5 Herpesvirus 4, Human and Crohn's disease**

- 1.Van Kruiningen, H. J. *et al.* Search for evidence of recurring or persistent viruses in Crohn's disease. *APMIS* **115**, 962–968 (2007).
- 2.Ueda, M. *et al.* [A case of acute disseminated encephalomyelitis associated with Epstein-Barr virus reactivation during infliximab therapy]. *Rinsho Shinkeigaku* **50**, 461–466 (2010).
- 3.Serrate, C. *et al.* Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. *Inflamm. Bowel Dis.* **15**, 1449–1451 (2009).
- 4.Salado, C. T. *et al.* Hemophagocytic lymphohistiocytosis in Crohn's disease associated with primary infection by Epstein-Barr virus. *Inflamm. Bowel Dis.* **17**, E143–144 (2011).
- 5.Ryan, J. L. *et al.* Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. *Dig. Dis. Sci.* **57**, 1887–1898 (2012).
- 6.Ross, S. *et al.* Epstein-Barr virus-associated lymphoproliferative disorder in Crohn disease treated with azathioprine. *J. Pediatr. Gastroenterol. Nutr.* **51**, 229–231 (2010).
- 7.Reijasse, D. *et al.* Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. *Inflamm. Bowel Dis.* **10**, 85–90 (2004).
- 8.Magin, W. S., Van Kruiningen, H. J. & Colombel, J.-F. Immunohistochemical search for viral and bacterial antigens in Crohn's disease. *J Crohns Colitis* **7**, 161–166 (2013).
- 9.Lobo, B., Mínguez, B., Molero, X. & Casellas, F. [Fever due to Epstein-Barr virus infection in Crohns disease]. *Med Clin (Barc)* **120**, 677–678 (2003).
- 10.Lavagna, A. *et al.* Infliximab and the risk of latent viruses reactivation in active Crohn's disease. *Inflamm. Bowel Dis.* **13**, 896–902 (2007).
- 11.Järnerot, G. & Lantorp, K. Antibodies to EB virus in cases of Crohn's disease. *N. Engl. J. Med.* **286**, 1215–1216 (1972).
- 12.Castrellon, A. *et al.* Crohn's disease complicated by primary gastrointestinal Hodgkin's lymphoma presenting with small bowel perforation. *J Gastrointest Liver*



*Dis* **18**, 359–361 (2009).

13. Bloch, D. B. *et al.* Decreased IL-10 production by EBV-transformed B cells from patients with VODI: implications for the virusesis of Crohn disease. *J. Allergy Clin. Immunol.* **129**, 1678–1680 (2012).

14. Angelucci, E., Cesarini, M., Caturelli, E. & Vernia, P. EBV hepatitis in a young Crohn's disease patient on prolonged remission with azathioprine. *Inflamm. Bowel Dis.* **17**, E1 (2011).

## **V5 Herpesvirus 4, Human and Inflammatory bowel disease**

1. Yanai, H., Shimizu, N., Nagasaki, S., Mitani, N. & Okita, K. Epstein-Barr virus infection of the colon with inflammatory bowel disease. *Am. J. Gastroenterol.* **94**, 1582–1586 (1999).

2. Wong, N. A. C. S. *et al.* Epstein-Barr virus infection in colorectal neoplasms associated with inflammatory bowel disease: detection of the virus in lymphomas but not in adenocarcinomas. *J. Pathol.* **201**, 312–318 (2003).

3. Weinberg, I. *et al.* Epstein-barr virus-related diarrhea or exacerbation of inflammatory bowel disease: diagnostic dilemma. *J. Clin. Microbiol.* **47**, 1588–1590 (2009).

4. Vos, A. C. W. *et al.* Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. *Inflamm. Bowel Dis.* **17**, 1837–1845 (2011).

5. Van Kruiningen, H. J. *et al.* Search for evidence of recurring or persistent viruses in Crohn's disease. *APMIS* **115**, 962–968 (2007).

6. Ueda, M. *et al.* [A case of acute disseminated encephalomyelitis associated with Epstein-Barr virus reactivation during infliximab therapy]. *Rinsho Shinkeigaku* **50**, 461–466 (2010).

7. Spieker, T. & Herbst, H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. *Am. J. Pathol.* **157**, 51–57 (2000).

8. Serrate, C. *et al.* Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. *Inflamm. Bowel Dis.* **15**, 1449–1451 (2009).

9. Sankaran-Walters, S. *et al.* Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. *J. Clin. Virol.* **50**, 31–36 (2011).

10. Salado, C. T. *et al.* Hemophagocytic lymphohistiocytosis in Crohn's disease associated with primary infection by Epstein-Barr virus. *Inflamm. Bowel Dis.* **17**, E143–144 (2011).

11. Ryan, J. L. *et al.* Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. *Dig. Dis. Sci.* **57**, 1887–1898 (2012).

12. Ross, S. *et al.* Epstein-Barr virus-associated lymphoproliferative disorder in Crohn disease treated with azathioprine. *J. Pediatr. Gastroenterol. Nutr.* **51**, 229–231 (2010).

13. Reijasse, D. *et al.* Epstein-Barr virus viral load in Crohn's disease: effect of

immunosuppressive therapy. *Inflamm. Bowel Dis.* **10**, 85–90 (2004).

14. Nishigami, T. *et al.* Concomitant adenocarcinoma and colonic non-Hodgkin's lymphoma in a patient with ulcerative colitis: a case report and molecular analysis. *Pathol. Res. Pract.* **206**, 846–850 (2010).

15. Magin, W. S., Van Kruiningen, H. J. & Colombel, J.-F. Immunohistochemical search for viral and bacterial antigens in Crohn's disease. *J Crohns Colitis* **7**, 161–166 (2013).

16. Losco, A. *et al.* Epstein-Barr virus-associated lymphoma in Crohn's disease. *Inflamm. Bowel Dis.* **10**, 425–429 (2004).

17. Li, S. & Borowitz, M. J. Primary Epstein-Barr virus-associated Hodgkin disease of the ileum complicating Crohn disease. *Arch. Pathol. Lab. Med.* **125**, 424–427 (2001).

18. Lavagna, A. *et al.* Infliximab and the risk of latent viruses reactivation in active Crohn's disease. *Inflamm. Bowel Dis.* **13**, 896–902 (2007).

19. Lavagna, A. *et al.* The hazardous burden of Herpesviridae in inflammatory bowel disease: the case of refractory severe ulcerative colitis. *Dig Liver Dis* **38**, 887–893 (2006).

20. Kofoed, K., Kiszka-Kanowitz, M., Albrechtsen, J. M. & Andersen, O. [Epstein-Barr virus-associated large B-cell lymphoma in a patient with colitis ulcerosa treated with azathioprine]. *Ugeskr. Laeg.* **170**, 1255 (2008).

21. Juul Ingvarsen, C., Ballegaard, V. C. & Homøe, P. [Fatal haemophagocytic lymphohistiocytosis and mononucleosis in a patient with colitis ulcerosa]. *Ugeskr. Laeg.* **174**, 1461–1462 (2012).

22. Järnerot, G. & Lantorp, K. Antibodies to EB virus in cases of Crohn's disease. *N. Engl. J. Med.* **286**, 1215–1216 (1972).

23. Grotsky, H. W. *et al.* Epstein-Barr virus and inflammatory bowel disease. *Experientia* **27**, 1474–1475 (1971).

24. Gehlert, T., Devergne, O. & Niedobitek, G. Epstein-Barr virus (EBV) infection and expression of the interleukin-12 family member EBV-induced gene 3 (EBI3) in chronic inflammatory bowel disease. *J. Med. Virol.* **73**, 432–438 (2004).

25. Dimitroulia, E., Pitiriga, V. C., Piperaki, E.-T., Spanakis, N. E. & Tsakris, A. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. *Dis. Colon Rectum* **56**, 322–327 (2013).

26. Daniel, F. *et al.* A steroid-refractory ulcerative colitis revealing Epstein-Barr virus/cytomegalovirus-positive colonic lymphoma. *Int J Colorectal Dis* **21**, 288–290 (2006).

27. Bloch, D. B. *et al.* Decreased IL-10 production by EBV-transformed B cells from patients with VODI: implications for the virusesis of Crohn disease. *J. Allergy Clin. Immunol.* **129**, 1678–1680 (2012).

28. Bertalot, G. *et al.* Evidence of Epstein-Barr virus infection in ulcerative colitis. *Dig Liver Dis* **33**, 551–558 (2001).

29. Bai, M. *et al.* Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature. *Scand. J. Gastroenterol.* **41**, 866–869 (2006).

30. Angelucci, E., Cesarini, M., Caturelli, E. & Vernia, P. EBV hepatitis in a young Crohn's disease patient on prolonged remission with azathioprine. *Inflamm. Bowel Dis.* **17**, E1 (2011).

## **V5 Herpesvirus 4, Human and Lung cancer**

1. Wee, J. *et al.* Why are East Asians more susceptible to several infection-associated cancers (carcinomas of the nasopharynx, stomach, liver, adenocarcinoma of the lung, nasal NK/T-cell lymphomas)? *Med. Hypotheses* **79**, 833–842 (2012).

2. Taoka, K. *et al.* Progressive transition of Epstein-Barr virus associated lymphoproliferative disease subtypes with the development of lung cancer. *Am. J. Hematol.* **84**, 600–603 (2009).

3. Lim, W.-T., Chuah, K. L., Leong, S. S., Tan, E. H. & Toh, C. K. Assessment of human papillomavirus and Epstein-Barr virus in lung adenocarcinoma. *Oncol. Rep.* **21**, 971–975 (2009).

4. Li, C., Zhang, S., Zhu, J. & Han, G. [Study on EB virus infection, LMP1 and Bcl-2 expression in lung cancer patients]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* **25**, 277–279 (2011).

5. Koshiol, J. *et al.* Epstein-Barr virus microRNAs and lung cancer. *Br. J. Cancer* **105**, 320–326 (2011).

6. Gómez-Román, J. J., Martínez, M. N., Fernández, S. L. & Val-Bernal, J. F. Epstein-Barr virus-associated adenocarcinomas and squamous-cell lung carcinomas. *Mod. Pathol.* **22**, 530–537 (2009).

## **V5 Herpesvirus 4, Human and Multiple sclerosis**

1. Zivadinov, R. *et al.* Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. *J. Neurol. Neurosurg. Psychiatr.* **80**, 620–625 (2009).

2. Villegas, E. *et al.* Low intrathecal immune response of anti-EBNA-1 antibodies and EBV DNA from multiple sclerosis patients. *Diagn. Microbiol. Infect. Dis.* **70**, 85–90 (2011).

3. Tzartos, J. S. *et al.* Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. *Neurology* **78**, 15–23 (2012).

4. Tselis, A. Evidence for viral etiology of multiple sclerosis. *Semin Neurol* **31**, 307–316 (2011).

5. Tselis, A. Epstein-Barr virus cause of multiple sclerosis. *Curr Opin Rheumatol* **24**, 424–428 (2012).

6. Sundqvist, E. *et al.* Epstein-Barr virus and multiple sclerosis: interaction with HLA. *Genes Immun.* **13**, 14–20 (2012).

7. Sternberg, Z. Autonomic dysfunction: a unifying multiple sclerosis theory, linking chronic cerebrospinal venous insufficiency, vitamin D(3), and Epstein-Barr virus. *Autoimmun Rev* **12**, 250–259 (2012).

8. Serafini, B. *et al.* Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal

- B-cell activation. *J. Neuropathol. Exp. Neurol.* **69**, 677–693 (2010).
- 9.Santón, A. *et al.* High frequency of co-infection by Epstein-Barr virus types 1 and 2 in patients with multiple sclerosis. *Mult. Scler.* **17**, 1295–1300 (2011).
  - 10.Salveti, M., Giovannoni, G. & Aloisi, F. Epstein-Barr virus and multiple sclerosis. *Curr. Opin. Neurol.* **22**, 201–206 (2009).
  - 11.Pohl, D. Epstein-Barr virus and multiple sclerosis. *J. Neurol. Sci.* **286**, 62–64 (2009).
  - 12.Pender, M. P., Csurhes, P. A., Pfluger, C. M. M. & Burrows, S. R. CD8 T cell deficiency impairs control of Epstein-Barr virus and worsens with age in multiple sclerosis. *J. Neurol. Neurosurg. Psychiatr.* **83**, 353–354 (2012).
  - 13.Pender, M. P. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. *Autoimmun Rev* **8**, 563–568 (2009).
  - 14.Pakpoor, J. *et al.* The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. *Mult. Scler.* **19**, 162–166 (2013).
  - 15.Owens, G. P. & Bennett, J. L. Trigger, virus, or bystander: the complex nexus linking Epstein-Barr virus and multiple sclerosis. *Mult. Scler.* **18**, 1204–1208 (2012).
  - 16.Nociti, V. *et al.* Epstein-Barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis. *J. Neuroimmunol.* **225**, 149–152 (2010).
  - 17.Niller, H. H., Wolf, H., Ay, E. & Minarovits, J. Epigenetic dysregulation of Epstein-Barr virus latency and development of autoimmune disease. *Adv. Exp. Med. Biol.* **711**, 82–102 (2011).
  - 18.Niino, M. Risk factors for multiple sclerosis: decreased vitamin D level and remote Epstein-Barr virus infection in the pre-clinical phase of multiple sclerosis. *J. Neurol. Neurosurg. Psychiatr.* **83**, 1135 (2012).
  - 19.Nielsen, T. R., Pedersen, M., Rostgaard, K., Frisch, M. & Hjalgrim, H. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. *Mult. Scler.* **13**, 420–423 (2007).
  - 20.Meier, U.-C., Giovannoni, G., Tzartos, J. S. & Khan, G. Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease virusesis and Trojan horse for Epstein-Barr virus entry to the central nervous system? *Clin. Exp. Immunol.* **167**, 1–6 (2012).
  - 21.Lünemann, J. D. Epstein-Barr virus in multiple sclerosis: a continuing conundrum. *Neurology* **78**, 11–12 (2012).
  - 22.Lucas, R. M. *et al.* Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. *Neurology* **77**, 371–379 (2011).
  - 23.Lossius, A., Johansen, J. N., Torkildsen, Ø., Vartdal, F. & Holmøy, T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation. *Viruses* **4**, 3701–3730 (2012).
  - 24.Lindsey, J. W. & Hatfield, L. M. Epstein-Barr virus and multiple sclerosis: cellular immune response and cross-reactivity. *J. Neuroimmunol.* **229**, 238–242 (2010).
  - 25.Khaki, M. *et al.* Evaluation of viral antibodies in Iranian multiple sclerosis patients. *Neurosciences (Riyadh)* **16**, 224–228 (2011).

- 26.Kakalacheva, K., Münz, C. & Lünemann, J. D. Viral triggers of multiple sclerosis. *Biochim. Biophys. Acta* **1812**, 132–140 (2011).
- 27.Hon, G. M., Hassan, M. S., van Rensburg, S. J., Erasmus, R. T. & Matsha, T. E. Assessment of Epstein-Barr virus in blood from patients with multiple sclerosis. *Metab Brain Dis* **27**, 311–318 (2012).
- 28.Gazouli, M. *et al.* NRAMP1 polymorphism and viral factors in Sardinian multiple sclerosis patients. *Can J Neurol Sci* **35**, 491–494 (2008).
- 29.Farrell, R. A. *et al.* Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. *Neurology* **73**, 32–38 (2009).
- 30.Décard, B. F. *et al.* Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. *J. Neurol. Neurosurg. Psychiatr.* **83**, 1170–1173 (2012).
- 31.Cossu, D. *et al.* Are Mycobacterium avium subsp. paratuberculosis and Epstein-Barr virus triggers of multiple sclerosis in Sardinia? *Mult. Scler.* **18**, 1181–1184 (2012).
- 32.Castellazzi, M. *et al.* Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. *Mult. Scler.* **16**, 883–887 (2010).
- 33.Banwell, B. *et al.* Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. *Lancet Neurol* **6**, 773–781 (2007).
- 34.Bagert, B. A. Epstein-Barr virus in multiple sclerosis. *Curr Neurol Neurosci Rep* **9**, 405–410 (2009).

## **V5 Herpesvirus 4, Human and Rheumatoid arthritis**

- 1.Yang, L. *et al.* Rheumatoid factors induce signaling from B cells, leading to Epstein-Barr virus and B-cell activation. *J. Virol.* **78**, 9918–9923 (2004).
- 2.Us, T., Cetin, E., Kaşifoğlu, N., Kaşifoğlu, T. & Akgün, Y. [Investigation of Epstein-Barr virus and herpes simplex virus markers by serological and molecular methods in patients with rheumatoid arthritis and systemic lupus erythematosus]. *Mikrobiyol Bul* **45**, 677–683 (2011).
- 3.Toussiot, E. & Roudier, J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. *Joint Bone Spine* **74**, 418–426 (2007).
- 4.Tournadre, A. *et al.* Cutaneous lymphoma associated with Epstein-Barr virus infection in 2 patients treated with methotrexate. *Mayo Clin. Proc.* **76**, 845–848 (2001).
- 5.Soubrier, M., Arrestier, S., Bouloudian, S., Dubost, J.-J. & Ristori, J.-M. Epstein-Barr virus infection associated hepatic lymphoma in a patient treated with methotrexate for rheumatoid arthritis. *Joint Bone Spine* **73**, 218–219 (2006).
- 6.Petrov, A. V. [Frequency of different infectious agents persistence in mononuclear leukocytes of blood and synovial fluid in patients with rheumatoid arthritis]. *Lik. Sprava* 28–32 (2005).
- 7.Lünemann, J. D. *et al.* Increased frequency of EBV-specific effector memory

CD8+ T cells correlates with higher viral load in rheumatoid arthritis. *J. Immunol.* **181**, 991–1000 (2008).

8.Lossius, A., Johansen, J. N., Torkildsen, Ø., Vartdal, F. & Holmøy, T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation. *Viruses* **4**, 3701–3730 (2012).

9.Kojima, M. *et al.* Distribution of Epstein-Barr virus in systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis) with associated lymphadenopathy: a study of 49 cases. *Int. J. Surg. Pathol.* **13**, 273–278 (2005).

10.Kojima, M. *et al.* Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. *Int. J. Surg. Pathol.* **14**, 43–48 (2006).

11.Jørgensen, K. T. *et al.* Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. *Ann. Rheum. Dis.* **67**, 860–866 (2008).

12.Davis, J. M., 3rd *et al.* A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis. *Arthritis Res. Ther.* **14**, R24 (2012).

13.Balandraud, N., Roudier, J. & Roudier, C. Epstein-Barr virus and rheumatoid arthritis. *Autoimmun Rev* **3**, 362–367 (2004).

14.Alvarez-Lafuente, R. *et al.* Potential relationship between herpes viruses and rheumatoid arthritis: analysis with quantitative real time polymerase chain reaction. *Ann. Rheum. Dis.* **64**, 1357–1359 (2005).

15.Alvarez-Lafuente, R. *et al.* Potential relationship between herpes viruses and rheumatoid arthritis: analysis with quantitative real time polymerase chain reaction. *Ann. Rheum. Dis.* **64**, 1357–1359 (2005).

## **V5 Herpesvirus 4, Human and Schizophrenia**

1.Wang, H., Yolken, R. H., Hoekstra, P. J., Burger, H. & Klein, H. C. Antibodies to infectious agents and the positive symptom dimension of subclinical psychosis: The TRAILS study. *Schizophr. Res.* **129**, 47–51 (2011).

2.Natsukari, N., Kulaga, H., Baker, I., Wyatt, R. J. & Masserano, J. M. Increased cyclic AMP response to forskolin in Epstein-Barr virus-transformed human B-lymphocytes derived from schizophrenics. *Psychopharmacology (Berl.)* **130**, 235–241 (1997).

3.Krause, D. *et al.* The association of infectious agents and schizophrenia. *World J. Biol. Psychiatry* **11**, 739–743 (2010).

4.Delisi, L. E. *et al.* Herpes simplex virus, cytomegalovirus and Epstein-Barr virus antibody titres in sera from schizophrenic patients. *Psychol Med* **16**, 757–763 (1986).

## **V5 Herpesvirus 4, Human and Systemic lupus erythematosus**

1. Zandman-Goddard, G. *et al.* Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. *Ann. N. Y. Acad. Sci.* **1173**, 658–663 (2009).
2. Yu, S.-F. *et al.* Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. *Med. Microbiol. Immunol.* **194**, 115–120 (2005).
3. Via, C. S. Implications of the parent-into-F1 model for human lupus virusesis: roles for cytotoxic T lymphocytes and viral viruss. *Curr Opin Rheumatol* **22**, 493–498 (2010).
4. Vaughan, J. H. The Epstein-Barr virus and systemic lupus erythematosus. *J. Clin. Invest.* **100**, 2939–2940 (1997).
5. Us, T., Cetin, E., Kaşifoğlu, N., Kaşifoğlu, T. & Akgün, Y. [Investigation of Epstein-Barr virus and herpes simplex virus markers by serological and molecular methods in patients with rheumatoid arthritis and systemic lupus erythematosus]. *Mikrobiyol Bul* **45**, 677–683 (2011).
6. Tsukamoto, N. *et al.* Long-term follow-up of EBV-positive lymphoproliferative disorders in a patient with systemic lupus erythematosus. *Med Mol Morphol* **44**, 237–241 (2011).
7. Tazi, I., Fehri, S., Elghrari, K., Ouazzani, T. & Benchemsi, N. [Systemic lupus erythematosus and Epstein-Barr virus]. *East. Mediterr. Health J.* **15**, 701–708 (2009).
8. Roszkowiak, B. & Niemir, Z. I. [Potential role of the Epstein-Barr virus in the virusesis of systemic lupus erythematosus and kidney diseases]. *Postepy Hig Med Dosw (Online)* **58**, 390–397 (2004).
9. Ramos-Casals, M. *et al.* Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. *Medicine (Baltimore)* **87**, 311–318 (2008).
10. Poole, B. D. *et al.* Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. *Autoimmun Rev* **8**, 337–342 (2009).
11. Poole, B. D., Scofield, R. H., Harley, J. B. & James, J. A. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. *Autoimmunity* **39**, 63–70 (2006).
12. Pender, M. P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. *Trends Immunol.* **24**, 584–588 (2003).
13. Parks, C. G. *et al.* Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. *Arthritis Rheum.* **52**, 1148–1159 (2005).
14. Moon, U. Y. *et al.* Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. *Arthritis Res. Ther.* **6**, R295–302 (2004).
15. Mitarnun, W. *et al.* Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis. *J Med Assoc Thai* **85**, 552–559 (2002).
16. McClain, M. T., Harley, J. B. & James, J. A. The role of Epstein-Barr virus in systemic lupus erythematosus. *Front. Biosci.* **6**, E137–147 (2001).

- 17.Lu, J. J. Y. *et al.* Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan. *Lupus* **16**, 168–175 (2007).
- 18.Lossius, A., Johansen, J. N., Torkildsen, Ø., Vartdal, F. & Holmøy, T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation. *Viruses* **4**, 3701–3730 (2012).
- 19.Larsen, M. *et al.* Exhausted cytotoxic control of Epstein-Barr virus in human lupus. *PLoS Pathog.* **7**, e1002328 (2011).
- 20.Kosminsky, S., de Menezes, R. C. & Coêlho, M. R. C. D. [Epstein-Barr virus infection in patients with systemic lupus erythematosus]. *Rev Assoc Med Bras* **52**, 352–355 (2006).
- 21.Kojima, M. *et al.* Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. *Int. J. Surg. Pathol.* **14**, 43–48 (2006).
- 22.Kawashiri, S. *et al.* Emergence of Epstein-Barr virus-associated haemophagocytic syndrome upon treatment of systemic lupus erythematosus. *Lupus* **15**, 51–53 (2006).
- 23.Kasapcopur, O. *et al.* Systemic lupus erythematosus due to Epstein-Barr virus or Epstein-Barr virus infection provoking acute exacerbation of systemic lupus erythematosus? *Rheumatol. Int.* **26**, 765–767 (2006).
- 24.Kang, I. *et al.* Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. *J. Immunol.* **172**, 1287–1294 (2004).
- 25.James, J. A. & Robertson, J. M. Lupus and Epstein-Barr. *Curr Opin Rheumatol* **24**, 383–388 (2012).
- 26.James, J. A., Harley, J. B. & Scofield, R. H. Epstein-Barr virus and systemic lupus erythematosus. *Curr Opin Rheumatol* **18**, 462–467 (2006).
- 27.James, J. A. *et al.* Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. *Arthritis Rheum.* **44**, 1122–1126 (2001).
- 28.James, J. A. *et al.* An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. *J. Clin. Invest.* **100**, 3019–3026 (1997).
- 29.Incaprera, M., Rindi, L., Bazzichi, A. & Garzelli, C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. *Clin. Exp. Rheumatol.* **16**, 289–294 (1998).
- 30.Huggins, M. L., Todd, I. & Powell, R. J. Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. *Rheumatol. Int.* **25**, 183–187 (2005).
- 31.Hongbo, C., Hongzhen, M., Lingzhi, H., Maosheng, X. & Mei, C. Secondary neuropsychiatric manifestations caused by Epstein-Barr virus encephalitis in a new onset systemic lupus erythematosus patient. *Rheumatol. Int.* **32**, 2321–2323 (2012).
- 32.Harley, J. B. & James, J. A. Epstein-Barr virus infection induces lupus autoimmunity. *Bull NYU Hosp Jt Dis* **64**, 45–50 (2006).
- 33.Gross, A. J., Hochberg, D., Rand, W. M. & Thorley-Lawson, D. A. EBV and systemic lupus erythematosus: a new perspective. *J. Immunol.* **174**, 6599–6607 (2005).
- 34.Esen, B. A. *et al.* Serologic response to Epstein-Barr virus antigens in patients



with systemic lupus erythematosus: a controlled study. *Rheumatol. Int.* **32**, 79–83 (2012).

35.Dror, Y. *et al.* Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. *Am. J. Kidney Dis.* **32**, 825–828 (1998).

36.Drabort, A. H., Duus, K. & Houen, G. Epstein-Barr virus and systemic lupus erythematosus. *Clin. Dev. Immunol.* **2012**, 370516 (2012).

37.Chen, C.-J. *et al.* High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. *J. Rheumatol.* **32**, 44–47 (2005).

38.Chan, A. C. L., Li, C. S., Cheuk, W. & Chan, J. K. C. Epstein-Barr virus associated leiomyosarcoma in a patient with systemic lupus erythematosus. *Pathology* **39**, 358–361 (2007).

39.Blank, M., Shoenfeld, Y. & Perl, A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. *Lupus* **18**, 1136–1143 (2009).

40.Berkun, Y. *et al.* Infectious antibodies in systemic lupus erythematosus patients. *Lupus* **18**, 1129–1135 (2009).

## **V5 Herpesvirus 4, Human and Type 2 diabetes**

1.Sugimoto, M. *et al.* WRN gene and other genetic factors affecting immortalization of human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. *Cancer Genet. Cytogenet.* **152**, 95–100 (2004).

2.Sesti, G. *et al.* Delayed intracellular dissociation of the insulin-receptor complex impairs receptor recycling and insulin processing in cultured Epstein-Barr virus-transformed lymphocytes from insulin-resistant subjects. *Diabetologia* **39**, 289–295 (1996).

3.Kadowaki, T. *et al.* Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. *Science* **240**, 787–790 (1988).

4.Casarin, R. C. V. *et al.* Influence of glycemic control on Epstein-Bar and Cytomegalovirus infection in periodontal pocket of type 2 diabetic subjects. *Arch. Oral Biol.* **55**, 902–906 (2010).

## **V5 Herpesvirus 4, Human and Ulcerative colitis**

1.Takeda, Y. *et al.* Demonstration of Epstein-Barr virus localized in the colonic and ileal mucosa of a patient with ulcerative colitis. *Gastrointest. Endosc.* **51**, 205–209 (2000).

2.Ryan, J. L. *et al.* Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. *Dig. Dis. Sci.* **57**, 1887–1898 (2012).

3.Russano de Paiva, G., Adolfo da Silva, N., Jr, March, M., Brousset, P. & Laurent, C. High frequency of Epstein-Barr virus-infected lymphocytes in pilonidal cysts. *Hum. Pathol.* **43**, 2241–2246 (2012).

4.Ohara, M. *et al.* Immunoglobulin G subclass distribution of human anticolon

antibodies in ulcerative colitis. *J. Gastroenterol. Hepatol.* **10**, 158–164 (1995).

5.Nishigami, T. *et al.* Concomitant adenocarcinoma and colonic non-Hodgkin's lymphoma in a patient with ulcerative colitis: a case report and molecular analysis. *Pathol. Res. Pract.* **206**, 846–850 (2010).

6.Lavagna, A. *et al.* The hazardous burden of Herpesviridae in inflammatory bowel disease: the case of refractory severe ulcerative colitis. *Dig Liver Dis* **38**, 887–893 (2006).

7.Kofoed, K., Kiszka-Kanowitz, M., Albrechtsen, J. M. & Andersen, O. [Epstein-Barr virus-associated large B-cell lymphoma in a patient with colitis ulcerosa treated with azathioprine]. *Ugeskr. Laeg.* **170**, 1255 (2008).

8.Juul Ingvardsen, C., Ballegaard, V. C. & Homøe, P. [Fatal haemophagocytic lymphohistiocytosis and mononucleosis in a patient with colitis ulcerosa]. *Ugeskr. Laeg.* **174**, 1461–1462 (2012).

9.Hibi, T. *et al.* In vitro anticolon antibody production by mucosal or peripheral blood lymphocytes from patients with ulcerative colitis. *Gut* **31**, 1371–1376 (1990).

10.Daniel, F. *et al.* A steroid-refractory ulcerative colitis revealing Epstein-Barr virus/cytomegalovirus-positive colonic lymphoma. *Int J Colorectal Dis* **21**, 288–290 (2006).

11.Bertalot, G. *et al.* Evidence of Epstein-Barr virus infection in ulcerative colitis. *Dig Liver Dis* **33**, 551–558 (2001).

## **V5 Herpesvirus 5, Human and Alcohol dependence**

1.Toghill, P. J., Williams, R. & Stern, H. Cytomegalovirus infection in chronic liver disease. *Gastroenterology* **56**, 936–937 (1969).

2.Stigendal, L., Hermodsson, S. & Olsson, R. Prevalence of markers of hepatotropic viruses in alcoholics with symptomatic liver cirrhosis or pancreatitis. *Scand. J. Gastroenterol.* **19**, 588–590 (1984).

3.Pol, S. *et al.* Herpesvirus infection of the respiratory tract in patients with alcoholic hepatitis. *Alcohol. Clin. Exp. Res.* **16**, 979–981 (1992).

4.Pan, H. *et al.* Chronic ethanol consumption inhibits hepatic natural killer cell activity and accelerates murine cytomegalovirus-induced hepatitis. *Alcohol. Clin. Exp. Res.* **30**, 1615–1623 (2006).

5.Laskus, T. *et al.* Prevalence of markers of hepatitis viruses in out-patient alcoholics. *J. Hepatol.* **15**, 174–178 (1992).

6.Laskus, T. *et al.* [Antibodies against Cytomegalovirus and Herpes simplex virus in alcoholics and drug addicts]. *Przegl Epidemiol* **45**, 262–266 (1991).

7.Faria, L. C. *et al.* Pneumocystis pneumonia: an opportunistic infection occurring in patients with severe alcoholic hepatitis. *Eur J Gastroenterol Hepatol* **20**, 26–28 (2008).

## **V5 Herpesvirus 5, Human and Alzheimer's disease (cognitive decline)**

1.Strandberg, T. E., Pitkala, K. H., Linnavuori, K. & Tilvis, R. S. Cognitive

impairment and infectious burden in the elderly. *Arch Gerontol Geriatr Suppl* 419–423 (2004). doi:10.1016/j.archger.2004.04.053

2.Blasko, I. *et al.* Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin. *J Psychiatr Res* **41**, 694–701 (2007).

3.Aiello, A. E. *et al.* The influence of latent viral infection on rate of cognitive decline over 4 years. *J Am Geriatr Soc* **54**, 1046–1054 (2006).

## **V5 Herpesvirus 5, Human and Bipolar disorder**

1.Yolken, R. H. & Torrey, E. F. Are some cases of psychosis caused by microbial agents? A review of the evidence. *Mol. Psychiatry* **13**, 470–479 (2008).

2.Torrey, E. F., Yolken, R. H. & Winfrey, C. J. Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. *Science* **216**, 892–894 (1982).

3.Tedla, Y. *et al.* Serum antibodies to *Toxoplasma gondii* and Herpesviridae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. *Ethiop. Med. J.* **49**, 211–220 (2011).

4.Prasad, K. M., Watson, A. M. M., Dickerson, F. B., Yolken, R. H. & Nimgaonkar, V. L. Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. *Schizophr Bull* **38**, 1137–1148 (2012).

5.Mortensen, P. B. *et al.* Neonatal antibodies to infectious agents and risk of bipolar disorder: a population-based case-control study. *Bipolar Disord* **13**, 624–629 (2011).

6.Martin, W. J. Simian cytomegalovirus-related stealth virus isolated from the cerebrospinal fluid of a patient with bipolar psychosis and acute encephalopathy. *Pathobiology* **64**, 64–66 (1996).

7.Lycke, E., Norrby, R. & Roos, B. E. A serological study on mentally ill patients with particular reference to the prevalence of herpes virus infections. *Br J Psychiatry* **124**, 273–279 (1974).

## **V5 Herpesvirus 5, Human and Bipolar disorder and schizophrenia**

1.Yolken, R. H. & Torrey, E. F. Are some cases of psychosis caused by microbial agents? A review of the evidence. *Mol. Psychiatry* **13**, 470–479 (2008).

2.Torrey, E. F., Yolken, R. H. & Winfrey, C. J. Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. *Science* **216**, 892–894 (1982).

3.Prasad, K. M., Watson, A. M. M., Dickerson, F. B., Yolken, R. H. & Nimgaonkar, V. L. Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. *Schizophr Bull* **38**, 1137–1148 (2012).

4.Mortensen, P. B. *et al.* Neonatal antibodies to infectious agents and risk of bipolar disorder: a population-based case-control study. *Bipolar Disord* **13**, 624–629 (2011).

5.Martin, W. J. Simian cytomegalovirus-related stealth virus isolated from the

cerebrospinal fluid of a patient with bipolar psychosis and acute encephalopathy. *Pathobiology* **64**, 64–66 (1996).

6.Lycke, E., Norrby, R. & Roos, B. E. A serological study on mentally ill patients with particular reference to the prevalence of herpes virus infections. *Br J Psychiatry* **124**, 273–279 (1974).

## **V5 Herpesvirus 5, Human and Breast cancer**

1.Tsai, J.-H. *et al.* Association of viral factors with non-familial breast cancer in Taiwan by comparison with non-cancerous, fibroadenoma, and thyroid tumor tissues. *J. Med. Virol.* **75**, 276–281 (2005).

2.Tsai, J.-H. *et al.* Relationship between viral factors, axillary lymph node status and survival in breast cancer. *J. Cancer Res. Clin. Oncol.* **133**, 13–21 (2007).

3.Taher, C. *et al.* High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. *PLoS ONE* **8**, e56795 (2013).

4.Richardson, A. K. *et al.* Cytomegalovirus, Epstein-Barr virus and risk of breast cancer before age 40 years: a case-control study. *Br. J. Cancer* **90**, 2149–2152 (2004).

5.Richardson, A. Is breast cancer caused by late exposure to a common virus? *Med. Hypotheses* **48**, 491–497 (1997).

6.Pandey, J. P. *et al.* Genetic markers of immunoglobulin G and susceptibility to breast cancer. *Hum. Immunol.* **73**, 1155–1158 (2012).

7.Melnick, M., Sedghizadeh, P. P., Allen, C. M. & Jaskoll, T. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. *Exp. Mol. Pathol.* **92**, 118–125 (2012).

8.Harkins, L. E. *et al.* Detection of human cytomegalovirus in normal and neoplastic breast epithelium. *Herpesviridae* **1**, 8 (2010).

9.Fagundes, C. P., Glaser, R., Malarkey, W. B. & Kiecolt-Glaser, J. K. Childhood adversity and herpesvirus latency in breast cancer survivors. *Health Psychol* **32**, 337–344 (2013).

10.Fagundes, C. P. *et al.* Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. *Brain Behav. Immun.* **26**, 394–400 (2012).

11.El-Shinawi, M. *et al.* Human cytomegalovirus infection enhances NF- $\kappa$ B/p65 signaling in inflammatory breast cancer patients. *PLoS ONE* **8**, e55755 (2013).

12.Cox, B. *et al.* Breast cancer, cytomegalovirus and Epstein-Barr virus: a nested case-control study. *Br. J. Cancer* **102**, 1665–1669 (2010).

## **V5 Herpesvirus 5, Human and Celiac disease**

1.Ter Meulen, C. G., Stronkhorst, A., Tan, I. & Bravenboer, B. Cytomegalovirus-associated gastric ulcers in a patient with celiac disease: coincidence or association? *Am. J. Gastroenterol.* **92**, 1933–1934 (1997).

2.Plot, L. *et al.* Infections may have a protective role in the etioviruses of celiac

disease. *Ann. N. Y. Acad. Sci.* **1173**, 670–674 (2009).

3. Meresse, B. *et al.* Reprogramming of CTLs into natural killer-like cells in celiac disease. *J. Exp. Med.* **203**, 1343–1355 (2006).

4. Kelly, E., Cullen, G., Aftab, A. R. & Courtney, G. Coeliac crisis presenting with cytomegalovirus hepatitis. *Eur J Gastroenterol Hepatol* **18**, 793–795 (2006).

## **V5 Herpesvirus 5, Human and Coronary heart disease**

1. Graham, J. A. *et al.* Viral infection induces de novo lesions of coronary allograft vasculopathy through a natural killer cell-dependent pathway. *Am. J. Transplant.* **9**, 2479–2484 (2009).

## **V5 Herpesvirus 5, Human and Crohn's disease**

1. Sinagra, E. *et al.* Early postoperative recurrence of severe Crohn's disease, with colonic involvement and associated human cytomegalovirus infection, treated with oral valganciclovir and adalimumab. *Inflamm. Bowel Dis.* **17**, E43–44 (2011).

2. Shahani, L. CMV infection complicating the diagnosis of Crohn's disease in an immunocompetent patient. *BMJ Case Rep* **2012**, (2012).

3. Samalin, E. *et al.* [Cytomegalovirus infection in a patient with Crohn's disease]. *Rev Med Interne* **24**, 477–480 (2003).

4. Roblin, X. *et al.* Prevalence of cytomegalovirus infection in steroid-refractory Crohn's disease. *Inflamm. Bowel Dis.* **18**, E1396–1397 (2012).

5. Rahbar, A. *et al.* Evidence of active cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases. *Inflamm. Bowel Dis.* **9**, 154–161 (2003).

6. Pickering, O., Weinstein, T. & Rubin, L. G. Fatal disseminated cytomegalovirus infection associated with infliximab and 6-mercaptopurine therapy in a child with Crohn disease. *Pediatr. Infect. Dis. J.* **28**, 556 (2009).

7. Olsen, S. & Gilbert, J. Cytomegalovirus infection in Crohn's colitis. *J R Soc Med* **97**, 335–336 (2004).

8. N'Guyen, Y. *et al.* Cytomegalovirus associated hemophagocytic lymphohistiocytosis in patients suffering from Crohn's disease treated by azathioprine: a series of four cases. *Inflamm. Bowel Dis.* **17**, E116–118 (2011).

9. Nakase, H., Yoshino, T., Honzawa, Y. & Chiba, T. Low prevalence of CMV infection in patients with Crohn's disease in comparison with ulcerative colitis: effect of different immune response on prevalence of CMV infection. *Dig. Dis. Sci.* **55**, 1498–1499 (2010).

10. Miquel, T. *et al.* Hemophagocytic syndrome in the course of Crohn's disease: possible association with cytomegalovirus infection. *Am. J. Gastroenterol.* **104**, 252 (2009).

11. Levesque, B. G., Pai, R. & Cartwright, C. A. Crohn's colitis complicated by cytomegalovirus infection. *Dig. Dis. Sci.* **54**, 1864–1867 (2009).

12. Le, S. T. T., Lee, S. S. K., Prideaux, L., Block, A. A. & Moore, G. T. C.

Primary cytomegalovirus ileitis complicated by massive gastrointestinal haemorrhage in a patient with steroid refractory Crohn's disease. *Intern Med J* **40**, 788–791 (2010).

13.Knösel, T., Schewe, C., Petersen, N., Dietel, M. & Petersen, I. Prevalence of infectious virus in Crohn's disease. *Pathol. Res. Pract.* **205**, 223–230 (2009).

14.Hommes, D. W., Sterringa, G., van Deventer, S. J. H., Tytgat, G. N. J. & Weel, J. The viruscity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. *Inflamm. Bowel Dis.* **10**, 245–250 (2004).

15.Hizawa, K. *et al.* [Crohn's ileocolitis with initially superimposed cytomegalovirus infection, resembling intestinal tuberculosis]. *Nihon Shokakibyō Gakkai Zasshi* **104**, 1733–1737 (2007).

16.Cascio, A., Iaria, C. & Fries, W. Cytomegalovirus pneumonia: a possible cause of death in patients with Crohn's disease. *Am. J. Gastroenterol.* **108**, 454 (2013).

17.Ben Hriz, F. *et al.* [Cytomegalovirus primary infection in a patient with Crohn's disease treated with azathioprine and anti-TNF alpha]. *Tunis Med* **87**, 545–546 (2009).

18.Adani, G. L., Avital, I., Ferrareso, C. & Aoki, T. CMV infection in severe refractory ulcerative and Crohn's colitis. *Am. J. Gastroenterol.* **96**, 3464–3465 (2001).

19.Aarnio, M. T. *et al.* Absence of cytomegalovirus from the gastrointestinal tract of patients with active Crohn's disease. *In Vivo* **26**, 151–155 (2012).

## **V5 Herpesvirus 5, Human and Inflammatory bowel disease**

1.Yi, F. *et al.* The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. *Viol. J.* **10**, 43 (2013).

2.Sipponen, T. *et al.* Human herpesvirus 6 and cytomegalovirus in ileocolonic mucosa in inflammatory bowel disease. *Scand. J. Gastroenterol.* **46**, 1324–1333 (2011).

3.Roblin, X. *et al.* Prevalence of cytomegalovirus infection in steroid-refractory Crohn's disease. *Inflamm. Bowel Dis.* **18**, E1396–1397 (2012).

4.Pillet, S., Pozzetto, B., Jarlot, C., Paul, S. & Roblin, X. Management of cytomegalovirus infection in inflammatory bowel diseases. *Dig Liver Dis* **44**, 541–548 (2012).

5.Nakase, H., Yoshino, T., Honzawa, Y. & Chiba, T. Low prevalence of CMV infection in patients with Crohn's disease in comparison with ulcerative colitis: effect of different immune response on prevalence of CMV infection. *Dig. Dis. Sci.* **55**, 1498–1499 (2010).

6.Miquel, T. *et al.* Hemophagocytic syndrome in the course of Crohn's disease: possible association with cytomegalovirus infection. *Am. J. Gastroenterol.* **104**, 252 (2009).

7.Maher, M. M. & Nassar, M. I. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. *Dig. Dis. Sci.* **54**, 2456–2462 (2009).

8.Lidar, M., Langevitz, P. & Shoenfeld, Y. The role of infection in inflammatory

bowel disease: initiation, exacerbation and protection. *Isr. Med. Assoc. J.* **11**, 558–563 (2009).

9.Lévêque, N. *et al.* Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. *J. Med. Virol.* **82**, 1694–1700 (2010).

10.Kim, J. J. *et al.* Cytomegalovirus infection in patients with active inflammatory bowel disease. *Dig. Dis. Sci.* **55**, 1059–1065 (2010).

11.Fpathfu, W. A. R., Nausheen, Y., Fpathkfu, R. A., Khudairi, A. A. & Nemenqani, D. Histopathological features of an incidental case of cytomegalovirus salpingitis in a patient with inflammatory bowel disease. *J Pak Med Assoc* **63**, 780–783 (2013).

12.Fpathfu, W. A. R., Nausheen, Y., Fpathkfu, R. A., Khudairi, A. A. & Nemenqani, D. Histopathological features of an incidental case of cytomegalovirus salpingitis in a patient with inflammatory bowel disease. *J Pak Med Assoc* **63**, 780–783 (2013).

13.Dzabic, M. & Rahbar, A. [Active HCMV infection behind acute inflammatory bowel disease. Causal role or epiphenomenon still to be proved]. *Lakartidningen* **105**, 1378–1381 (2008).

14.Antonelli, E. *et al.* Intestinal superinfections in patients with inflammatory bowel diseases. *J Crohns Colitis* **6**, 154–159 (2012).

15.Aarnio, M. T. *et al.* Absence of cytomegalovirus from the gastrointestinal tract of patients with active Crohn's disease. *In Vivo* **26**, 151–155 (2012).

## **V5 Herpesvirus 5, Human and Lung cancer**

1.Melnick, M., Sedghizadeh, P. P., Allen, C. M. & Jaskoll, T. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. *Exp. Mol. Pathol.* **92**, 118–125 (2012).

2.Matthes, T., Kaiser, L., Weber, D., Kurt, A.-M. & Dietrich, P.-Y. Cytomegalovirus colitis--a severe complication after standard chemotherapy. *Acta Oncol* **41**, 704–706 (2002).

3.D'Journo, X. B. *et al.* Molecular detection of microorganisms in distal airways of patients undergoing lung cancer surgery. *Ann. Thorac. Surg.* **93**, 413–422 (2012).

4.Allen, T. C., Bag, R., Zander, D. S. & Cagle, P. T. Cytomegalovirus infection masquerading as carcinoma in a lung transplant patient. *Arch. Pathol. Lab. Med.* **129**, e1–3 (2005).

## **V5 Herpesvirus 5, Human and Multiple sclerosis**

1.Zivadinov, R. *et al.* Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. *Neurol. Res.* **28**, 262–269 (2006).

2.Waubant, E. *et al.* Common viruses associated with lower pediatric multiple sclerosis risk. *Neurology* **76**, 1989–1995 (2011).

3.Sanadgol, N. *et al.* Prevalence of cytomegalovirus infection and its role in total immunoglobulin pattern in Iranian patients with different subtypes of multiple sclerosis. *New Microbiol.* **34**, 263–274 (2011).

4.Pirko, I. *et al.* CMV infection attenuates the disease course in a murine model of multiple sclerosis. *PLoS ONE* **7**, e32767 (2012).

5.Pakpoor, J., Pakpoor, J., Disanto, G., Giovannoni, G. & Ramagopalan, S. V. Cytomegalovirus and multiple sclerosis risk. *J Neurol* **260**, 1658–1660 (2013).

6.Mancuso, R. *et al.* Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis. *J. Med. Virol.* **79**, 192–199 (2007).

7.Djelilovic-Vranic, J. & Alajbegovic, A. Role of early viral infections in development of multiple sclerosis. *Med Arh* **66**, 37–40 (2012).

8.Barzilai, O. *et al.* Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. *Ann. N. Y. Acad. Sci.* **1108**, 567–577 (2007).

## **V5 Herpesvirus 5, Human and Obesity**

1.Semenza, J. C., Svederud, I., Medin, E., Orrskog, S. & Tsoleva, S. Mapping ongoing European research activities examining the infectious aetiology of chronic conditions. *Clin. Microbiol. Infect.* (2012). doi:10.1111/1469-0691.12030

2.Rubicz, R. *et al.* Seroprevalence of 13 common viruses in a rapidly growing U.S. minority population: Mexican Americans from San Antonio, TX. *BMC Res Notes* **4**, 433 (2011).

3.Roubalová, K., Broz, J., Hrubá, D., Hýblová, M. & Kraml, P. Prevalence of active infection with *Chlamydia pneumoniae* and human cytomegalovirus in patients with type II diabetes mellitus. *Folia Microbiol. (Praha)* **52**, 287–290 (2007).

4.Roberts, B. W. & Cech, I. Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus. *South. Med. J.* **98**, 686–692 (2005).

5.Kanda, T., Yokosuka, O. & Suzuki, Y. Prolonged hepatitis caused by cytomegalovirus and non-alcoholic steatohepatitis in 16-year-old obese boy. *Eur. J. Pediatr.* **164**, 212–215 (2005).

6.Chen, S. *et al.* Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study. *Immun Ageing* **9**, 18 (2012).

7.Blans, M. C. A. *et al.* Infection induced inflammation is associated with erectile dysfunction in men with diabetes. *Eur. J. Clin. Invest.* **36**, 497–502 (2006).

## **V5 Herpesvirus 5, Human and Rheumatoid arthritis**

1.Vallet, H., Houitte, R., Azria, A. & Mariette, X. Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis. *J. Rheumatol.* **38**, 965–966 (2011).

2.Tnani, N. *et al.* [Management of cytomegalovirus infections in patients treated



with immunosuppressive drugs for chronic inflammatory diseases]. *Rev Med Interne* **29**, 305–310 (2008).

3. Shimojima, Y., Ishii, W., Matsuda, M., Nakazawa, H. & Ikeda, S.-I. Cytomegalovirus-induced infectious mononucleosis-like syndrome in a rheumatoid arthritis patient treated with methotrexate and infliximab. *Intern. Med.* **49**, 937–940 (2010).

4. Pontikaki, I. *et al.* [Side effects of anti-TNF $\alpha$  therapy in juvenile idiopathic arthritis]. *Reumatismo* **58**, 31–38 (2006).

5. Pierer, M. *et al.* Association of anticytomegalovirus seropositivity with more severe joint destruction and more frequent joint surgery in rheumatoid arthritis. *Arthritis Rheum.* **64**, 1740–1749 (2012).

6. Petrov, A. V. [Frequency of different infectious agents persistence in mononuclear leukocytes of blood and synovial fluid in patients with rheumatoid arthritis]. *Lik. Sprava* 28–32 (2005).

7. Nakajima, H., Takayama, A., Ito, T. & Yoshikawa, T. Acute encephalomyelitis with multiple herpes viral reactivations during abatacept therapy. *BMJ Case Rep* **2013**, (2013).

8. Izumikawa, K. *et al.* Adult Still's disease associated with cytomegalovirus infection. *J. Infect. Chemother.* **13**, 114–117 (2007).

9. Husney, R., Privman, V. & Sepkowitz, D. Patient with rheumatoid arthritis on methotrexate with multiple infecting organisms causing gastritis. *BMJ Case Rep* **2013**, (2013).

10. Gräni, C., Ramsay, D., Vogt, M. & Langenegger, T. Cytomegalovirus infection in a patient with rheumatoid arthritis on low-dose methotrexate. *Joint Bone Spine* **78**, 421–422 (2011).

11. Davis, J. M., 3rd *et al.* A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis. *Arthritis Res. Ther.* **14**, R24 (2012).

12. Amenomori, M. *et al.* Cytomegalovirus-associated hemophagocytic syndrome in a patient with adult onset Still's disease. *Clin. Exp. Rheumatol.* **23**, 100–102 (2005).

## V5 Herpesvirus 5, Human and Schizophrenia

1. Torrey, E. F. *et al.* Cytomegalovirus and schizophrenia. *CNS Drugs* **20**, 879–885 (2006).

2. Tedla, Y. *et al.* Serum antibodies to *Toxoplasma gondii* and Herpesviridae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. *Ethiop. Med. J.* **49**, 211–220 (2011).

3. Shirts, B. H. *et al.* Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia. *Schizophr. Res.* **106**, 268–274 (2008).

4. Shirts, B. H. *et al.* Polymorphisms in MICB are associated with human herpes virus seropositivity and schizophrenia risk. *Schizophr. Res.* **94**, 342–353 (2007).

5. Novotná, M. *et al.* Probable neuroimmunological link between *Toxoplasma* and

cytomegalovirus infections and personality changes in the human host. *BMC Infect. Dis.* **5**, 54 (2005).

6.Niebuhr, D. W., Millikan, A. M., Yolken, R., Li, Y. & Weber, N. S. Results from a hypothesis generating case-control study: herpes family viruses and schizophrenia among military personnel. *Schizophr Bull* **34**, 1182–1188 (2008).

7.Leweke, F. M. *et al.* Antibodies to infectious agents in individuals with recent onset schizophrenia. *Eur Arch Psychiatry Clin Neurosci* **254**, 4–8 (2004).

8.Krause, D. *et al.* The association of infectious agents and schizophrenia. *World J. Biol. Psychiatry* **11**, 739–743 (2010).

9.Dickerson, F. B., Boronow, J. J., Stallings, C. R., Origoni, A. E. & Yolken, R. H. Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. *Am J Psychiatry* **160**, 2234–2236 (2003).

10.Dickerson, F. *et al.* Deficit schizophrenia: association with serum antibodies to cytomegalovirus. *Schizophr Bull* **32**, 396–400 (2006).

11.Børglum, A. D. *et al.* Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. *Mol. Psychiatry* (2013). doi:10.1038/mp.2013.2

12.Bamne, M. *et al.* Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure. *Schizophr Bull* **38**, 1149–1154 (2012).

## **V5 Herpesvirus 5, Human and Systemic lupus erythematosus**

1.Tsai, W. P. *et al.* Cytomegalovirus infection causes morbidity and mortality in patients with autoimmune diseases, particularly systemic lupus: in a Chinese population in Taiwan. *Rheumatol. Int.* **32**, 2901–2908 (2012).

2.Strasser, C. *et al.* Opportunistic cytomegalovirus infection causing colonic perforation in a patient with systemic lupus erythematosus. *Lupus* **21**, 449–451 (2012).

3.Ramos-Casals, M. *et al.* Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. *Medicine (Baltimore)* **87**, 311–318 (2008).

4.Pérez-Mercado, A. E. & Vilá-Pérez, S. Cytomegalovirus as a trigger for systemic lupus erythematosus. *J Clin Rheumatol* **16**, 335–337 (2010).

5.Kwon, C. M. *et al.* A case of acute pericarditis with hemophagocytic syndrome, cytomegalovirus infection and systemic lupus erythematosus. *Rheumatol. Int.* **28**, 271–273 (2008).

6.Fujimoto, D., Matsushima, A., Nagao, M., Takakura, S. & Ichiyama, S. Risk factors associated with elevated blood cytomegalovirus pp65 antigen levels in patients with autoimmune diseases. *Mod Rheumatol* **23**, 345–350 (2013).

7.Berkun, Y. *et al.* Infectious antibodies in systemic lupus erythematosus patients. *Lupus* **18**, 1129–1135 (2009).

8.Barzilai, O., Ram, M. & Shoenfeld, Y. Viral infection can induce the production of autoantibodies. *Curr Opin Rheumatol* **19**, 636–643 (2007).

9.Barber, C., Gold, W. L. & Fortin, P. R. Infections in the lupus patient: perspectives on prevention. *Curr Opin Rheumatol* **23**, 358–365 (2011).

## **V5 Herpesvirus 5, Human and Type 2 diabetes**

1.Roberts, B. W. & Cech, I. Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus. *South. Med. J.* **98**, 686–692 (2005).

2.Leung Ki, E.-L. *et al.* Cytomegalovirus infection and new-onset post-transplant diabetes mellitus. *Clin Transplant* **22**, 245–249 (2008).

## **V5 Herpesvirus 5, Human and Ulcerative colitis**

1.Yoshino, T. *et al.* Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. *Digestion* **84**, 3–9 (2011).

2.Yamamoto-Furusho, J. K., de León-Rendón, J. L. & Rodas, L. [Infection frequency in patients with chronic idiopathic ulcerative colitis]. *Rev Gastroenterol Mex* **77**, 186–192 (2012).

3.Xue, M., Chen, S. J., Wang, L. J., Du, Y. & Si, J. M. Cytomegalovirus: a probable cause of steroid-refractory ulcerative colitis. *J Dig Dis* **14**, 160–165 (2013).

4.Roblin, X. & Del Tedesco, E. Tacrolimus in the management of hospitalized patients with steroid-refractory ulcerative colitis: don't forget cytomegalovirus! *Inflamm. Bowel Dis.* **19**, E67–68 (2013).

5.Omiya, M., Matsushita, M., Tanaka, T., Kawamata, S. & Okazaki, K. The absence of large ulcer predicts latent cytomegalovirus infection in ulcerative colitis with positive mucosal viral assay. *Intern. Med.* **49**, 2277–2282 (2010).

6.Nguyen, M., Bradford, K., Zhang, X. & Shih, D. Q. Cytomegalovirus Reactivation in Ulcerative Colitis Patients. *Ulcers* **2011**, (2011).

7.Nakase, H., Yoshino, T., Honzawa, Y. & Chiba, T. Low prevalence of CMV infection in patients with Crohn's disease in comparison with ulcerative colitis: effect of different immune response on prevalence of CMV infection. *Dig. Dis. Sci.* **55**, 1498–1499 (2010).

8.Nakase, H., Yamamoto, S., Matsuura, M., Honzawa, Y. & Chiba, T. Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. *Aliment. Pharmacol. Ther.* **32**, 510–511 (2010).

9.Nakase, H., Matsuura, M. & Chiba, T. Potential role of granulocyte/monocyte adsorptive apheresis for ulcerative colitis with concomitant CMV infection. *Aliment. Pharmacol. Ther.* **33**, 497–498; author reply 498 (2011).

10.Mun, J. I. *et al.* A case of hemophagocytic syndrome in a patient with fulminant ulcerative colitis superinfected by cytomegalovirus. *Korean J. Intern. Med.* **28**, 352–355 (2013).

11.Mokhtari, M., Tavakkoli, H., Rafiee, A. & Dibaj, R. Assessment of relationship between active ulcerative colitis and cytomegalovirus infection among Iranian patients. *Adv Biomed Res* **1**, 19 (2012).

12.Matsumura, K. *et al.* Establishment of a novel mouse model of ulcerative colitis with concomitant cytomegalovirus infection: in vivo identification of

cytomegalovirus persistent infected cells. *Inflamm. Bowel Dis.* **19**, 1951–1963 (2013).

13.Kopylov, U. *et al.* Cytomegalovirus positive ulcerative colitis: A single center experience and literature review. *World J Gastrointest Pathophysiol* **4**, 18–23 (2013).

14.Kim, Y. S. *et al.* The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. *J. Clin. Gastroenterol.* **46**, 51–56 (2012).

15.Iyer, V. H., Augustine, J., Pulimood, A. B., Ajampur, S. S. R. & Ramakrishna, B. S. Correlation between coinfection with parasites, cytomegalovirus, and *Clostridium difficile* and disease severity in patients with ulcerative colitis. *Indian J Gastroenterol* **32**, 115–118 (2013).

16.Criscuoli, V., Rizzuto, M. R., Montalbano, L., Gallo, E. & Cottone, M. Natural history of cytomegalovirus infection in a series of patients diagnosed with moderate-severe ulcerative colitis. *World J. Gastroenterol.* **17**, 633–638 (2011).

17.Chiba, M., Abe, T., Tsuda, S. & Ono, I. Cytomegalovirus infection associated with onset of ulcerative colitis. *BMC Res Notes* **6**, 40 (2013).

18.Charles, P. *et al.* Cytomegalovirus colitis complicating ulcerative colitis treated with adalimumab. *Scand. J. Gastroenterol.* **45**, 509–510 (2010).

19.Baryshnikov, E. N., Drozdov, V. N., Shuliat'ev, I. S., Parfenov, A. I. & Lazebnik, L. B. [Cytomegalovirus infection in patients with ulcerative colitis]. *Eksp Klin Gastroenterol* 25–28 (2010).

20.Barahona-Garrido, J. *et al.* Cytomegalovirus infection in patients who required colectomy for toxic megacolon or severe steroid-refractory ulcerative colitis. *Dig. Dis. Sci.* **55**, 867–868 (2010).

## **V5 Human Papillomavirus and Alcohol dependence**

1.Weiderpass, E. *et al.* Alcoholism and risk for cancer of the cervix uteri, vagina, and vulva. *Cancer Epidemiol. Biomarkers Prev.* **10**, 899–901 (2001).

## **V5 Human Papillomavirus and Breast cancer**

1.Simões, P. W. *et al.* Prevalence of human papillomavirus in breast cancer: a systematic review. *Int. J. Gynecol. Cancer* **22**, 343–347 (2012).

2.Sigaroodi, A. *et al.* Human papillomavirus is associated with breast cancer in the north part of Iran. *ScientificWorldJournal* **2012**, 837191 (2012).

3.Pereira Suarez, A. L. *et al.* Presence of human papilloma virus in a series of breast carcinoma from Argentina. *PLoS ONE* **8**, e61613 (2013).

4.Mou, X. *et al.* Low prevalence of human papillomavirus (HPV) in Chinese patients with breast cancer. *J. Int. Med. Res.* **39**, 1636–1644 (2011).

5.Li, N. *et al.* Human papillomavirus infection and sporadic breast carcinoma risk: a meta-analysis. *Breast Cancer Res. Treat.* **126**, 515–520 (2011).

6.Joshi, D. & Buehring, G. C. Are viruses associated with human breast cancer? Scrutinizing the molecular evidence. *Breast Cancer Res. Treat.* **135**, 1–15 (2012).

7.Herrera-Goepfert, R., Khan, N. A., Koriyama, C., Akiba, S. & Pérez-Sánchez, V.

M. High-risk human papillomavirus in mammary gland carcinomas and non-neoplastic tissues of Mexican women: no evidence supporting a cause and effect relationship. *Breast* **20**, 184–189 (2011).

8.Hedau, S. *et al.* Breast cancer and human papillomavirus infection: no evidence of HPV etiology of breast cancer in Indian women. *BMC Cancer* **11**, 27 (2011).

9.Hedau, S. *et al.* Breast cancer and human papillomavirus infection: no evidence of HPV etiology of breast cancer in Indian women. *BMC Cancer* **11**, 27 (2011).

10.Glenn, W. K. *et al.* Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. *PLoS ONE* **7**, e48788 (2012).

11.Frega, A. *et al.* Evaluation of E6 and E7 mRNA expression in HPV DNA positive breast cancer. *Eur. J. Gynaecol. Oncol.* **33**, 164–167 (2012).

12.Antonsson, A. *et al.* High prevalence of human papillomaviruses in fresh frozen breast cancer samples. *J. Med. Virol.* **83**, 2157–2163 (2011).

13.Alam, S. *et al.* Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells. *Mol. Cancer* **10**, 97 (2011).

14.Aguayo, F. *et al.* Human papillomavirus and Epstein-Barr virus infections in breast cancer from Chile. *Infect. Agents Cancer* **6**, 7 (2011).

## **V5 Human Papillomavirus and Coronary heart disease**

1.Kuo, H.-K. & Fujise, K. Human papillomavirus and cardiovascular disease among U.S. women in the National Health and Nutrition Examination Survey, 2003 to 2006. *J. Am. Coll. Cardiol.* **58**, 2001–2006 (2011).

## **V5 Human Papillomavirus and Crohn's disease**

1.Walsh, A. J. *et al.* Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* (2013). doi:10.1016/j.crohns.2013.02.019

2.Savoye, G. & Lerebours, E. Abnormal Pap smears in women with Crohn's disease: is there a role for defensin deficiency? *Am. J. Gastroenterol.* **103**, 1046–1047; author reply 1047 (2008).

3.Kuhlgatz, J. *et al.* Human papilloma virus infection in a recurrent squamous cell carcinoma associated with severe Crohn's disease. *Inflamm. Bowel Dis.* **11**, 84–86 (2005).

4.Kane, S., Khatibi, B. & Reddy, D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. *Am. J. Gastroenterol.* **103**, 631–636 (2008).

5.Frisch, M. *et al.* Benign anal lesions, inflammatory bowel disease and risk for high-risk human papillomavirus-positive and -negative anal carcinoma. *Br. J. Cancer* **78**, 1534–1538 (1998).

6.Beaugerie, L., Sokol, H. & Seksik, P. Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. *Dig Dis* **27**, 375–381 (2009).

7. Al-Ghamdi, A. *et al.* Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. *Gynecol. Oncol.* **84**, 94–101 (2002).

## **V5 Human Papillomavirus and Inflammatory bowel disease**

1. Zabana, Y. *et al.* Cervical dysplasia in immunosuppressed IBD women. *Inflamm. Bowel Dis.* **15**, 1774 (2009).

2. Yoshitake, N. *et al.* Human papillomavirus infection is involved in the development of colonic squamous cell dysplasia in ulcerative colitis-associated carcinogenesis. *Inflamm. Bowel Dis.* **13**, 1319–1321 (2007).

3. Seksik, P. *et al.* Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. *Aliment. Pharmacol. Ther.* **29**, 1106–1113 (2009).

4. Savoye, G. & Lerebours, E. Abnormal Pap smears in women with Crohn's disease: is there a role for defensin deficiency? *Am. J. Gastroenterol.* **103**, 1046–1047; author reply 1047 (2008).

5. Kuhlgatz, J. *et al.* Human papilloma virus infection in a recurrent squamous cell carcinoma associated with severe Crohn's disease. *Inflamm. Bowel Dis.* **11**, 84–86 (2005).

6. Kane, S., Khatibi, B. & Reddy, D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. *Am. J. Gastroenterol.* **103**, 631–636 (2008).

7. Kane, S. Abnormal Pap smears in inflammatory bowel disease. *Inflamm. Bowel Dis.* **14**, 1158–1160 (2008).

8. Jacobson, D. L. *et al.* Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. *Inflamm. Bowel Dis.* **19**, 1441–1449 (2013).

9. Greenberg, R., Greenwald, B., Roth, J. S., Ioffe, O. & Cross, R. Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine. *Dig. Dis. Sci.* **53**, 760–764 (2008).

10. Ali, T., Yun, L., Shapiro, D., Madhoun, M. F. & Bronze, M. Viral infections in patients with inflammatory bowel disease on immunosuppressants. *Am. J. Med. Sci.* **343**, 227–232 (2012).

11. Al-Bawardy, B., Fine, S., Lafond, J., Doran, A. & Borum, M. L. Missing cohort: Inflammatory bowel disease patients at increased risk for cervical dysplasia may be undervaccinated for HPV. *Inflamm. Bowel Dis.* **18**, 797 (2012).

## **V5 Human Papillomavirus and Lung cancer**

1. Zhang, E.-Y. & Tang, X.-D. Human papillomavirus type 16/18 oncoproteins: potential therapeutic targets in non-smoking associated lung cancer. *Asian Pac. J. Cancer Prev.* **13**, 5363–5369 (2012).

2. Wu, D.-W. *et al.* Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer. *Am. J. Pathol.* **181**, 1796–1806 (2012).

3. Wang, J.-L. *et al.* Human papillomavirus infections as a marker to predict overall survival in lung adenocarcinoma. *Int. J. Cancer* (2013). doi:10.1002/ijc.28349
4. Van Boerdonk, R. A. A. *et al.* High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis. *J Thorac Oncol* **8**, 711–718 (2013).
5. Tung, M.-C. *et al.* Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer. *Cancer* (2013). doi:10.1002/cncr.28220
6. Syrjänen, K. Detection of human papillomavirus in lung cancer: systematic review and meta-analysis. *Anticancer Res.* **32**, 3235–3250 (2012).
7. Storey, R. *et al.* Detection of Immunoglobulin G against E7 of Human Papillomavirus in Non-Small-Cell Lung Cancer. *J Oncol* **2013**, 240164 (2013).
8. Restrepo, C. S., Chen, M. M., Martinez-Jimenez, S., Carrillo, J. & Restrepo, C. Chest neoplasms with infectious etiologies. *World J Radiol* **3**, 279–288 (2011).
9. Ohtomo, R. *et al.* Anal canal neuroendocrine carcinoma associated with squamous intraepithelial neoplasia: a human papillomavirus 18-related lesion. *Pathol. Int.* **62**, 356–359 (2012).
10. Márquez-Medina, D. *et al.* Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib. *Arch. Bronconeumol.* **49**, 79–81 (2013).
11. Khoury, J. D. *et al.* Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq. *J. Virol.* **87**, 8916–8926 (2013).
12. Kato, T. *et al.* EGFR mutations and human papillomavirus in lung cancer. *Lung Cancer* **78**, 144–147 (2012).
13. Galvan, A. *et al.* Testing of human papillomavirus in lung cancer and non-tumor lung tissue. *BMC Cancer* **12**, 512 (2012).
14. Fodero, C. *et al.* Molecular diagnostics of pulmonary metastasis from cervical cancer. *Pathologica* **105**, 21–23 (2013).
15. Chen, S.-P. *et al.* Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients. *Ann. Thorac. Surg.* **95**, 1196–1203 (2013).

## **V5 Human Papillomavirus and Multiple sclerosis**

1. Sutton, I., Lahoria, R., Tan, I., Clouston, P. & Barnett, M. CNS demyelination and quadrivalent HPV vaccination. *Mult. Scler.* **15**, 116–119 (2009).
2. Gold, M. S. & McIntyre, P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. *Sex Health* **7**, 320–324 (2010).

## **V5 Human Papillomavirus and Obesity**

1. Jung, U. S. *et al.* Decreased prevalence of high-risk human papillomavirus infection is associated with obesity. *Eur. J. Gynaecol. Oncol.* **34**, 70–74 (2013).

2.Gu, W., Chen, C. & Zhao, K.-N. Obesity-associated endometrial and cervical cancers. *Front Biosci (Elite Ed)* **5**, 109–118 (2013).

3.Lee, J. K., So, K. A., Piyathilake, C. J. & Kim, M. K. Mild obesity, physical activity, calorie intake, and the risks of cervical intraepithelial neoplasia and cervical cancer. *PLoS ONE* **8**, e66555 (2013).

## **V5 Human Papillomavirus and Rheumatoid arthritis**

1.Shi, J., Sun, X., Zhao, Y., Zhao, J. & Li, Z. Prevalence and significance of antibodies to citrullinated human papilloma virus-47 E2345-362 in rheumatoid arthritis. *J. Autoimmun.* **31**, 131–135 (2008).

2.Rojo-Contreras, W. *et al.* Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. *Lupus* **21**, 365–372 (2012).

3.Rojo Contreras, W. *et al.* [Prevalence and cervical human papilloma virus associated factors in patients with rheumatoid arthritis]. *Ginecol Obstet Mex* **76**, 9–17 (2008).

## **V5 Human Papillomavirus and Systemic lupus erythematosus**

1.Yu, S.-L. *et al.* Antagonist-mediated down-regulation of Toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. *Arthritis Res. Ther.* **14**, R80 (2012).

2.Tam, L.-S. *et al.* Natural history of cervical papilloma virus infection in systemic lupus erythematosus - a prospective cohort study. *J. Rheumatol.* **37**, 330–340 (2010).

3.Tam, L.-S., Chan, A. Y. K., Chan, P. K. S., Chang, A. R. & Li, E. K. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. *Arthritis Rheum.* **50**, 3619–3625 (2004).

4.Sundsford, A. *et al.* BK and JC viruses in patients with systemic lupus erythematosus: prevalent and persistent BK viruria, sequence stability of the viral regulatory regions, and nondetectable viremia. *J. Infect. Dis.* **180**, 1–9 (1999).

5.Santana, I. U., Gomes, A. do N., Lyrio, L. D., Rios Grassi, M. F. & Santiago, M. B. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. *Clin. Rheumatol.* **30**, 665–672 (2011).

6.Rojo-Contreras, W. *et al.* Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. *Lupus* **21**, 365–372 (2012).

7.Nath, R. *et al.* High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. *Arthritis Rheum.* **57**, 619–625 (2007).

8.Mok, C. C., Ho, L. Y., Fong, L. S. & To, C. H. Immunogenicity and safety of a



quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. *Ann. Rheum. Dis.* **72**, 659–664 (2013).

9.Lyrio, L. D. C. *et al.* Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. *Rheumatol. Int.* **33**, 335–340 (2013).

10.Lee, Y.-H. *et al.* Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. *J. Korean Med. Sci.* **25**, 1431–1437 (2010).

11.Klumb, E. M. *et al.* Are women with lupus at higher risk of HPV infection? *Lupus* **19**, 1485–1491 (2010).

12.Dreyer, L., Faurschou, M., Mogensen, M. & Jacobsen, S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. *Arthritis Rheum.* **63**, 3032–3037 (2011).

13.CostaPinto, L. *et al.* Prevalence of Chlamydia trachomatis endocervical infection in systemic lupus erythematosus patients and evaluation of the risk for HPV-induced lesions. *Rheumatol. Int.* **33**, 631–636 (2013).

14.Abud-Mendoza, C. *et al.* Decreased blood levels of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV). *Arch. Dermatol. Res.* **305**, 117–123 (2013).

## **V5 Human Papillomavirus and Ulcerative colitis**

1.Yoshitake, N. *et al.* Human papillomavirus infection is involved in the development of colonic squamous cell dysplasia in ulcerative colitis-associated carcinogenesis. *Inflamm. Bowel Dis.* **13**, 1319–1321 (2007).

2.Yantiss, R. K. *et al.* Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. *Am. J. Surg. Pathol.* **33**, 572–582 (2009).

3.Wieland, U. *et al.* Novel human papillomavirus (HPV) DNA sequences from recurrent cutaneous and mucosal lesions of a stoma-carrier. *J. Invest. Dermatol.* **111**, 164–168 (1998).

4.Moss, S. F. & Blaser, M. J. Mechanisms of disease: Inflammation and the origins of cancer. *Nat Clin Pract Oncol* **2**, 90–97; quiz 1 p following 113 (2005).

5.Kong, C. S., Welton, M. L. & Longacre, T. A. Role of human papillomavirus in squamous cell metaplasia-dysplasia-carcinoma of the rectum. *Am. J. Surg. Pathol.* **31**, 919–925 (2007).

6.Kane, S., Khatibi, B. & Reddy, D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. *Am. J. Gastroenterol.* **103**, 631–636 (2008).

7.Greenberg, R., Greenwald, B., Roth, J. S., Ioffe, O. & Cross, R. Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine. *Dig. Dis. Sci.* **53**, 760–764 (2008).

8.Gilbert, J. M., Mann, C. V., Scholefield, J. & Domizio, P. The aetiology and surgery of carcinoma of the anus, rectum and sigmoid colon in Crohn's disease. Negative correlation with human papillomavirus type 16 (HPV 16). *Eur J Surg Oncol* **17**, 507–513 (1991).

9.Frisch, M. *et al.* Benign anal lesions, inflammatory bowel disease and risk for

high-risk human papillomavirus-positive and -negative anal carcinoma. *Br. J. Cancer* **78**, 1534–1538 (1998).

10.Dzeletovic, I., Pasha, S. & Leighton, J. A. Human papillomavirus-related rectal squamous cell carcinoma in a patient with ulcerative colitis diagnosed on narrow-band imaging. *Clin. Gastroenterol. Hepatol.* **8**, e47–48 (2010).